



UNIVERSITY OF KWAZULU-NATAL  
GAG-PROTEASE DRIVEN VIRAL REPLICATION 
CAPACITY AMONG HIV-1 SUBTYPES: IMPLICATIONS 




Omotayo Oluwaremilekun Farinre: 216073965  
   
Supervisor: Prof. Thumbi Ndung’u 





   
A thesis submitted in fulfilment of the academic requirements for the degree of 
Doctor of Philosophy in Virology in the School of Laboratory Medicine and 
Medical Sciences, HIV Pathogenesis Programme, Doris Duke Medical Research 
Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal.   
2020 
 
This project represents original work done by the author and where others have made 
contributions it has been acknowledged in the text. The experimental work described in this 
thesis was performed at the HIV Pathogenesis Programme, in the Hasso-Plattner Research 
Laboratory, from June 2016 to March 2020 in the Doris Duke Medical Research Institute, 
Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa, 




Omotayo O. Farinre:  _____________________ Date: ___________ 
 
 
As the candidate’s supervisors, we agree to the submission of this thesis. 
 
 
Prof. Thumbi Ndung’u: _______________________ Date: ____________ 
 
 


















I, Omotayo Oluwaremilekun Farinre, declare that   
  
i. The research reported in this thesis, is my original work, except where otherwise 
indicated.  
 
ii. This thesis has not been submitted for any degree or examination at any other university 
or tertiary institution.   
iii. This thesis does not contain other person’s data, pictures, graphs, or other information, 
unless specifically stated as being sourced from other people.   
iv. This thesis does not contain other persons’ writing, unless specifically acknowledged 
as being sourced from other scientists. Where other written sources have been quoted, 
then:   
a. Their words have been re-written, but the general information attributed to them 
has been referenced.   
b. Where exact words have been used, the writing has been placed inside quotation 
marks, and referenced.   
v. Where I have reproduced a publication of which I am author, I have indicated in detail 
which part of the publication was written by myself alone and have fully acknowledged 
that publication.   
vi. This thesis does not contain text, graphics or tables copied and pasted from the internet, 
unless specifically acknowledged, and the source being detailed in the thesis and in the 










Omotayo Farinre, Kamini Gounder, Tarylee Reddy, Marcel Tongo, Jonathan Hare, Beth 
Chaplin, Jill Gilmour, Phyllis Kanki, Jaclyn K. Mann, Thumbi Ndung’u. Subtype-specific 
differences in Gag-protease replication capacity of HIV-1 isolates from East and West 




Statement   
 
This manuscript has been reproduced in part non-continuously throughout the thesis. The 
candidate performed the experiments described in this paper, and where others made 
contributions it has been duly acknowledged in the text. The candidate drafted this publication 













Conference contributions  
1. Omotayo Farinre, Kamini Gounder, Marcel Tongo, Jonathan Hare, Jill Gilmour, 
Jaclyn Mann, & Thumbi Ndung’u. HIV-1 Isolates from West Africa Show Higher 
Fitness than to those from East Africa. The Frontiers in Retrovirology Conference, 11-
13 September 2018, Leuven, Belgium, Abstract 157, 
 Retrovirology 2018, 15 (Suppl 1): O17. Presented by Jaclyn K. Mann  
  
2. Omotayo Farinre, Kamini Gounder, Marcel Tongo, Jonathan Hare, Jill Gilmour, 
Jaclyn Mann, & Thumbi Ndung’u. HIV-1 Recombinant Viruses from West Africa 
Display Higher Replication Capacity Compared to Recombinants from East Africa. 
HIV research for prevention (HIVR4P): From research to impact Conference on the 21-














I dedicate this work to my personal Lord and Saviour, Jesus Christ for giving me the strength 
push to the end even when my own wisdom and efforts failed me. 
I also dedicate this work to my wife and children; Funmi, Tobi, Timi and Tomisin. Words are 
insufficient to express my gratitude for your patience, forbearance, and support throughout 


















This work was supported by the Poliomyelitis Research Foundation (PRF), the South African 
Department of Science and Innovation through the National Research Foundation (South 
African Research Chairs Initiative), the Victor Daitz Foundation and the International AIDS 
Initiative ((UKZNRSA1001). Additional funding was provided by the Sub-Saharan African 
Network for TB/HIV Research Excellence (SANTHE), a DELTAS Africa Initiative [grant # 
DEL-15-006]. The DELTAS Africa Initiative is an independent funding scheme of the African 
Academy of Sciences (AAS)’s Alliance for Accelerating Excellence in Science in Africa 
(AESA) and supported by the New Partnership for Africa’s Development Planning and 
Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust [grant # 
107752/Z/15/Z] and the UK government. 
 
I would also like to thank Professor Thumbi Ndung’u (Prof.) for granting me the opportunity 
to pursue my PhD at the HIV Pathogenesis Programme. Your mature, gentle, patience, kind 
nature and approach towards managing me as student and giving me some room to make 
mistakes and learn from them have been exceptional and exemplary. I am particularly inspired 
by your keen desire to develop critical mass of scientists on the African continent, and this 
shows in how you mentor your students. I am grateful to God for your support throughout this 
journey without which I may not have had the courage to finish. 
 
I also want to thank God for my Co-supervisor in the person of Dr. Jaclyn K. Mann (Jaclyn). 
If it were not for you taking my request to pursue a PhD with HPP to Prof. Thumbi, I would 
not have been in HPP in the first place. I cannot forget in a hurry your contribution to my 
growth, your laser precision approach towards research, critical thought, strict principles and 
very importantly time-management and planning qualities I still hope to learn from you. 
I am grateful to our collaborators who graciously donated plasma samples for this project such 
as Dr. Marcel Tongo who donated the Cameroonian samples, Dr. Hannah O. Ajoge who 
donated the Nigerian samples, and to Prof. Phyllis Kanki who donated the Senegalese samples 
and Beth Chaplin who assisted in amplifying the Senegalese samples. I will also thank Dr. Jill 
Gilmour, Dr. Jonathan Hare and the entire IAVI Protocol-C team for believing in this work 
enough to graciously donate the East African samples used for this study.  
 
I would like to thank our Laboratory Manager at the Hasso-Plattner in HPP, in the person of 
Keshni Hiramen. She and her team work very hard to support postgraduate students who use 
the laboratory and to ensure that everything I needed for my experiments was made available 
to me and were in good working order. I would also like to thank my fellow students and 
colleagues whom we weathered the difficult storm of long and failed experiments together. I 
would like to thank my sister from Kenya Dr. Doty Ojwach for all her encouragement and 
putting me through most of the laboratory techniques I am now familiar with, Noni whom we 
are bracing this PhD storm together, Dr. Funsho Ogunshola, Dr. Omolara Baiyeghuni, Dr. 
Kewreshni Naidoo. I would like to appreciate the administrative team of Mrs. Tarryn Leslie 
and Mr. Silvester Olupot for their support. I would also like to say a big thank you to all my 
office colleagues Sithembile, Qiniso, Miriam, Anele, Nombali, Trevor and Delon. You all 
made my stay memorable. 
 
To my mother Mrs. Tolulope Oluwatosin Farinre who is my number one fan, always praying, 
cheering, rooting, and believing in me even when I doubt myself. Thank you so much mum. 
To my sisters Ayes and Temiloobs who have been calling me Dr. Tayo for the last two years, 
and I have been telling them it is premature, well your wishes are coming true, thank you both 




The HIV-1 epidemic in sub-Saharan Africa is heterogeneous with diverse unevenly distributed 
subtypes and regional differences in prevalence. Subtype-specific differences in disease 
progression rate and transmission efficiency have been reported, but the underlying biological 
mechanisms have not been fully characterized. In this study, I tested the hypothesis that the 
subtypes prevalent in the East African epidemic, where adult prevalence rate is higher, have 
lower viral replication capacity (VRC) than their West African counterparts where adult 
prevalence rates are lower.  
Materials and methods: 
Gag-protease sequencing was performed on plasma samples from 213 and 160 antiretroviral-
naïve participants from West and East Africa, respectively. Online bioinformatic tools were 
used to infer HIV-1 subtypes and recombination patterns.  Replication capacities of patient-
derived gag-protease chimeric viruses from West (n=178) and East (n=114) Africa were 
determined using a green fluorescent protein reporter-based cell assay. Subtype and regional 
differences in viral replication capacity and amino acid variants impacting replication capacity 
were identified using appropriate statistical methods.  
Results: 
Subtypes identified in West Africa were CRF02_AG (65%, n=139), G (7%, n=15), A3 (5%, 
n=10), other CRFs (12%, n=26), various pure subtypes (9%, n=19) and A1G recombinants 
(2%, n=4). Subtypes A1 (64%, n=103), D (22%, n=35), AD (11%, n=17) and AC (3%, n=5) 
were identified in East Africa. Chimeric viruses from West Africa had significantly higher 
VRC compared to those from East Africa (p < 0.0001), with subtype-specific differences found 
among strains within West and East Africa (p < 0.0001). Recombination patterns showed a 
preference for subtypes D, G or J rather than subtype A in the p6 region of gag, with evidence 
that subtype-specific differences in this region impact viral replication capacity. Furthermore, 
the Gag A83V polymorphism was associated with reduced viral replication capacity in 
CRF02_AG (median < 0.86).  HLA-A*23:01 (p = 0.0014) and HLA-C*07:01 (p = 0.002) were 
associated with significantly lower viral replication capacity in subtype A infected individuals 
from East Africa.  
Conclusion: 
Overall, the data showed that viruses from West Africa displayed higher replication capacity 
than those from East Africa, which is consistent with the hypothesis that lower viral replication 
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Since the identification of the human immunodeficiency virus (HIV) as the etiologic agent of 
the acquired immunodeficiency syndrome (AIDS) almost four decades ago (1-3), over 60 
million people have been infected globally, with an excess of 35 million currently living with 
the virus (3-6).  AIDS is a set of symptoms and illnesses that develop because of advanced HIV 
infection, whereby the host immune system becomes wholly compromised. In 1981, the United 
States Centers for Disease Control and Prevention (CDC) reported a characteristic set of 
symptoms which included Pneumocystis carinii pneumonia and Kaposi’s sarcoma that 
appeared to be prevalent within a community of homosexual men in the United States (7-9). 
These would later turn out to be the first set of AIDS-related cases reported (7). Since then, the 
epidemic has grown widely, and extended beyond homosexual men into the general population. 
Sub-Saharan Africa currently accounts for about 70% of the global burden of HIV infections 
(2-5). Over the years, the development of highly active antiretroviral therapy (HAART) and 
increased public awareness programs facilitated a significant reduction of the epidemic 
globally. However, the financial burden of life-long use of medication, patient non-adherence, 
social stigma among others are some of the challenges impeding the effectiveness of HAART 
globally. To complement the efficacy of HAART, the development of a safe, effective, and 
affordable vaccine against HIV infection remains a priority to reduce viral transmission. 
Unfortunately, this has remained elusive due to the characteristic genetic diversity of HIV        
(2, 5, 10). I will give a brief history of HIV from its origins and discovery, its biology, 
pathogenesis, disease progression, host immune responses and conclude with the rationale for 
the current project in this chapter. 
 
1.2  Initial isolation of HIV 
HIV is a lentivirus, a genus within the retroviridae family (1, 3). In 1983, Francoise Barre 
Sinuossi and colleagues reported the isolation of a virus from the lymph node of a homosexual 
man suffering from lymphadenopathy syndrome (LAS) which they named the 
Lymphadenopathy Associated Virus (LAV) (1, 9). Thereafter, the Gallo and Levy groups also 
independently reported the isolation of a human T-lymphotropic virus (HTLV III) (11), and an 
AIDS-related virus (ARV) (12) from patients within their respective studies. However, further 
characterization of these isolates showed that they shared similar biological properties with the 
LAV, indicating that they were the same (1, 13). To resolve the problem of having different 
names for the same isolate, a sub-committee was inaugurated and empowered by the 
International Committee on Taxonomy of Viruses to propose a unifying name. The proposed 
and adopted name for the isolates became the human immunodeficiency virus (HIV) (1, 14).  
1.2.1 Origins of HIV 
Following the discovery and isolation of HIV, it became imperative to understand the route of 
its introduction into the human population and factors that aided its efficient host-adaptation 
(3). HIV represents multiple distinct cross-species transmissions; lentiviruses were known to 
be more prevalent in non-human mammals prior to the discovery of HIV (3, 15-18)  as 
summarised in Table 1.1. Retrospective sequence and phylogenetic analyses revealed distinct 
cross-species transmission events that led to the introduction of HIV into the human population 
(16). The search began for animal lentiviruses that could have been the source of HIV into the 
human population. Phylogenetic analysis showed that HIV was most closely related to 
lentiviruses found in non-human primates called simian immunodeficiency viruses (SIVs) (3, 























































































































































































































































































































































































































1.2.2 Primate reservoir theory 
Forty different species of primates had been shown to harbour SIVs (6, 18, 20), indicating 
primates as reservoirs of the ancestral viruses that were transmitted into the human population 
(3, 15). Evidence to support this theory includes, similarities in the viral genome organization 
between SIVs and HIV, phylogenetic relatedness, the prevalence of SIVs in their natural hosts, 
a geographic coincidence of natural hosts of SIVs and the epicentre of the epidemic as well as 
plausible routes of transmission (15)  as shown in Figures 1.1 and 1.2.  
1.2.3 Primate sources of HIV-1 & HIV-2 
The origin of HIV-1 was resolved in 1989 when a closely related virus was isolated from 
captive chimpanzees Pan troglodytes troglodytes (Ptt) in Gabon; the virus was designated 
SIVcpz (20). Corbet and colleagues were able to isolate additional samples of SIVcpz from 
wild chimpanzees (Ptt) (21, 22). Phylogenetic analyses showed that this virus gave rise to the 
Group M viruses responsible for the global pandemic and the N group that is largely restricted 
in West-Central Africa, while group O viruses were introduced into the human population by 
gorillas -Gorilla gorilla (SIVgor). The source of HIV-2 was also confirmed in the same year 
to be from sooty mangabey monkeys (SIVsmm) (3, 16). Phylogenetic analyses of 
mitochondrial DNA (mtDNA) obtained from African primates by Gagneux et al., (1999) 
showed four distinct sub-species of chimpanzees namely Pan troglodytes verus, Pan 
troglodytes ellioti, Pan troglodytes troglodytes and Pan troglodytes schweinfurthii and two 
main sub-species of gorilla- Gorilla gorilla and Gorilla beringei all spread across sub-Saharan 
Africa (10, 20, 23). My discussion hereafter will focus on HIV-1 since it is the subject of this 
study. 
 
Figure 1.1:  Distribution of non-human primates in West-Central Africa 
Figure 1.2: Phylogenetic analysis showing SIV and HIV relatedness 
 
Figure 1.1: Map of West-Central Africa, showing the ranges of chimpanzee subspecies (colour 
coded). The gold circle denotes the region in southeast Cameroon where SIVcpz strains closely 
related to HIV-1 group M are found. (20). and Figure 1.2 Evolutionary relationship of SIVcpz, 
SIVgor, and HIV-1 strains based on neighbour-joining phylogenetic analysis of partial env/nef 





1.2.4 HIV-1 host adaptation 
Fitness is a parameter that measures the sum of all characteristics of a pathogen that enables it 
to successfully transmit its genetic material from one generation to another within its immediate 
environment and has been associated with the rate of transmission in HIV-1 infections (24, 25). 
HIV-1 effectively adapted to its human hosts through several mechanisms including the 
transmission of mutation-prone viral particles that exist as a population of genetic variants or 
quasi-species within a single infection leading to positive selection of the fittest genetic variants 
(22, 26). HIV-1 has a short generation time, high mutation rate, high copy numbers and 
recombination of segments of its genome between circulating viruses of different clades (27-
29) facilitates its fitness. Variation in its envelope (env) sequence length and glycosylation 
patterns facilitate the utilization of receptors and co-receptors for viral entry into target cells. 
High levels of intra-host amino acid variation within its hyper-variable (V1V2) region 
facilitates viral escape from immune effector functions such as antibodies and cytotoxic T-
lymphocytes (CTLs) (26). Other examples of viral adaptation mechanisms include the 
inhibition of host antiviral immunity proteins such as the apolipoprotein-B mRNA editing 
enzyme catalytic polypeptide-like 3G (APOBEC3G) which inhibits the process of reverse 
transcription in HIV-1 (30), tripartite motif 5α (TRIM5α) which inhibits viral uncoating step 
(31) and tetherin which inhibits viral budding and the release of virions from infected cells 
(32). The entire sum of the viral characteristics plus the host cell environment, which includes 
the collection of CD4+, CD8+ cells and antibodies at the disposal of the host immune system 





1.2.5 Treatment and prevention strategies 
Antiretroviral therapy (ART) lowers patient viral load to undetectable levels, thereby reducing 
the risks of further transmission (33); a concept called treatment as prevention (34). Following 
positive diagnosis of HIV-1 infected individuals, the World Health Organization (WHO) 
recommends the test and treat initiative, which simply encourages global public health systems 
to treat all infected individuals immediately, and not wait for depletion of CD4+ cells to 
200/mm3 (35, 36). ART, however is unable to completely eradicate virus infected cells from 
the body (33), but successfully targets different steps in the viral replication cycle. There are 
currently, six classes of ARTs in clinical use namely: the nucleoside and non-nucleoside 
reverse transcription inhibitors, protease inhibitors, integrase inhibitors, the fusion inhibitor 
(enfuvirtide (T-20)), and the chemokine receptor antagonist (maraviroc) (37). ART regimens 
vary from country to country (33). Prevention strategies recommended by the WHO (35, 38) 
include advocacy for sexual health education, access to voluntary counselling and testing 
(VCT) services, advocating use of condoms between sexual partners and high-risk groups like 
sex workers and men who have sex with men (MSMs). Biomedical interventions have also not 
been left out in the prevention strategy against HIV-1 infection and transmission. Pre-exposure 
prophylaxis (PrEP) is given to high-risk groups like health workers, sex workers and MSMs 
(39-42). Also, the administration of short course of nevirapine during labour to prevent mother 
to child transmissions (MTCT) (43). Vaginal microbicides developed for women have also 
been shown to be moderately effective against HIV-1 acquisition, although not efficacious 
enough for licensure (39). Unfortunately, vaccine development efforts have failed to overcome 
the genetic diversity of HIV-1, although some concepts are showing promise and undergoing 
further testing (5, 44-46). 
 
 
1.3 HIV epidemiology 
The HIV-1 epidemic remains a global public health concern with an estimated 37.9 million 
people currently infected (47). The pattern of transmission varies across regions based on adult 
prevalence and viral genetic composition. Some regions like Europe, Americas, and Australia 
experience a concentrated pattern of transmission where infection is high among key 
populations such as men that have sex with men (MSM) and intravenous drug users (IDUs), 
but generally low within the general population. Even in sub-Saharan Africa where the 
population prevalence rate of HIV-1 is high, key population groups are disproportionately 
affected (48-53). Global adult prevalence is reported to have stabilized at 0.8% between 2001 
and 2007 (49), with a decline in new infections largely due to the successful expansion of ART 
coverage in poor developing countries resulting in the aversion of about 5.2 million deaths 
between 1995 and 2010 (54, 55). Adult HIV prevalence is highest within sub-Saharan Africa 
(5%), followed by the Caribbean (1%), Eastern Europe and Central Asia (0.8%), Central and 
South America (0.5%), South and Southeast Asia (0.3%), and East Asia (0.1%) (50). 
Heterosexual transmission is largely responsible for the spread of the virus globally (48, 49), 
although other modes have been reported in key populations such as IDUs and MSMs, mother-
to-child transmission (MTCT) and sharing of contaminated equipment in clinical settings (56). 
Sub-Saharan Africa bears about 70% of the global burden of HIV-1 infection with an estimated 
25.6 million currently living with the virus (47). However, prevalence rates in sub-Saharan 
Africa are heterogenous. Specifically, West Africa is reported to have an adult prevalence rate 
below 2%, except for Nigeria and Côte d'Ivoire with a prevalence of 5% and 11% respectively, 
while East Africa on the other hand has a higher prevalence rate above 5%, with Southern 
Africa having the highest prevalence rate of about 20% (48, 57-59).  
 
 
1.3.1 HIV global subtype distribution 
A major characteristic of HIV-1 is its genetic diversity. The virus evolves spontaneously in the 
absence of selection pressure and is found in infected persons in the form of a swarm of 
genetically diverse population termed quasi-species (60, 61). Viral evolution and thus diversity 
are driven by the multiple cross-species transmission events from non- human primates, the 
error prone RT (10-4/nt) enzyme, high viral turnover (1010 particles/day), high mutation rate (3 
× 10-5 mutations per base pair per cycle) and host immune-selection (24, 61, 62). HIV-1 
subtype distribution varies from region to region. The most recent estimates show subtype C 
as the most prevalent subtype globally, accounting for about 46.6% of all infections, while B 
(12.1%), A (10.3%), CRF02_AG (7.7%), CRF01_AE (5.3%), G (4.6%), and D (2.7%) are less 
common. Subtypes F, H, J and K combined account for 0.9%. Other circulating recombinant 
forms CRFs account for 3.7%, while unique recombinant forms (URFs) account for 6.1% of 
total infections (51). These subtypes are unevenly distributed globally with subtype A being 
predominant in Central and East Africa, and Eastern Europe, subtype B in Western and Central 
Europe, Americas, Australia, North Africa, and Middle East. Subtype C is predominant in 
Southern Africa, India, and Ethiopia. Subtype D on the other hand is locally predominant in 
East Africa especially Uganda, while G is predominantly found in West Africa, particularly 
Nigeria. CRF02_AG is the most predominant subtype in West Africa (6, 57, 60-64). The 
epidemic in sub-Saharan Africa is notably heterogeneous, with West-central Africa having the 
most genetically diverse epidemic globally. This genetic variation in HIV may have an impact 
on accurate diagnosis, disease progression, treatment, and development of a safe and effective 




1.3.2 HIV-1 classification system 
Characteristics of viruses like transmissibility, pathogenesis and immunogenicity are 
determined by viral evolution and host genetic composition. Viral genetic factors play a critical 
role in virulence, accurate diagnosis, vaccine design and epidemiological outlook required to 
predict and possibly prevent future outbreaks (63, 68). Prior to 1992, HIV-1 strains were 
classified based on their geographical origin; namely North American and African variants. 
However, as more isolates began to emerge, a robust classification system based on 
phylogenetic analyses of env coding sequences was implemented (63, 68). HIV-1 is classified 
into 4 groups namely M (Major) (69), O (Outlier) (70), N (Non-major) (71), and a rare P (72) 
group. Group M variants are the most common and thus responsible for global infection, while 
other groups are restricted to West-Central Africa (3, 73, 74). Group M viruses are classified 
into 10 discrete clades or subtypes namely (A-D, F-H, J, K) as shown in Figure 1.3 and very 
recently, subtype ‘L’ was identified from archived samples collected from the Democratic 
Republic of Congo (DRC) (75). The first set of subtypes classified were A, B, C, D & E. These 
isolates varied in their env sequences by about 30% and by 14% in the gag sequences. Sub-
subtypes are a category of viral isolates closely related to a specific subtype lineage, but not 
distant enough to be identified as a new subtype. For example, subtype A has sub-subtypes A1-
A7 (76, 77) and recently subtype D has been shown to have sub-subtypes D1-D3 (77) (Figure 
1.4). An alternative classification system is based on viral co-receptor usage (78), however, 
classification based on viral genetic variation is more commonly used. Observed increase in 
complexity of newly identified HIV-1 strains called for the re-evaluation of HIV-1 
nomenclature and classification. A 1999 meeting to resolve this challenge was convened to 
properly articulate a new classification system that would maintain historical consistencies with 
already existing literature; details of the outcomes of this meeting are fully described in (68), 
which surmised that phylogenetic and distance analysis must be used to identify new subtypes 
and a branching index of 0.66 has been used as an acceptable cut-off to determine genetic 
distance (76, 78). 
 
Figure 1.3: Updated classification of HIV-1 subtypes 
 





Figure 1.3 Updated classification of HIV-1 group M lineages. Figure 1.4: Maximum 
likelihood phylogenetic analysis of near full-length genome sequences of subtypes A and 
subtype D (77). 
 
 
Figure 1.4: New sub-sub types for A and D 
1.3.2.1 Circulating recombinant forms 
Circulating recombinant forms (CRFs) of HIV-1 group M represent a recombinant lineage that 
plays a critical role in regional pandemics. A CRF must share an identical genome structure 
that descends from the same recombination event (68). Generally, when people think of CRFs, 
the tendency is to presume that the recombination occurs because of fragment breakage and re-
joining as is the case for double stranded deoxy-ribonucleic acid (dsDNA); however, this is 
inaccurate. CRFs are formed due to phenomenon known as template switching which occurs 
during the reverse transcription process in a dually infected cell. This is what leads to the 
recombination event (57, 60, 76). The naming system for CRFs include the acronym ‘CRF’, 
followed by a number to reflect the order in which it was identified in relation to previously 
identified CRFs and two letters to identify the subtype composition; for example, CRF02_AG 
is the second CRF identified and has components of subtype A and G in its genome. In the 
event that there are more than 2 subtype components within the genome it is referred to as a 
complex and designated ‘cpx’ for example CRF11_cpx (68). Currently, over a 100 CRFs have 
been identified according to the Los Alamos HIV database 
(https://www.hiv.lanl.gov/content/sequence/HIV/CRFs/CRFs.html). CRF01_AE and 
CRF02_AG are the most prominent. Subtype ‘E’ was initially identified in the env, but was not 
identified in gag, hence it did not ‘meet’ the criteria for becoming an independent subtype. In 
gag, it appeared to be more closely related to subtype A. At the 2000 HIV-1 classification 
meeting, it was proposed that subtype ‘E’ be designated CRF01_AE because it represented a 
putative recombinant (68), and to keep with historical consistencies of previous literature 
referring to it as subtype E. It is proposed that CRF01_AE formed early during the HIV-1 
epidemic, and it is critical in regional epidemics in Asia and south east Asia, though it emerged 
from Central Africa (6, 68). CRF02_AG also plays a critical role in regional epidemic in 
Western and Central Africa. It is the most prevalent CRF, appearing to also have been formed 
by an early recombination event at the start of the epidemic. It was initially thought to be a 
‘pure’ subtype, while subtype ‘G’ was thought to be a recombinant. However, time to most 
recent common ancestor (tMRCA) analysis has shown that the ancestral sequences of pure 
subtypes A and G predate that of CRF02_AG. This confirms that CRF02_AG is indeed a 
recombinant of pure subtype A and G (6, 71, 79). Figure 1.5 shows the genome map of 
CRF01_AE and CRF02_AG. 
 
1.3.2.2 Unique recombinant forms 
Unique recombinant forms (URFs) refer to unique mosaic sequences that currently lack 
evidence of onward transmission and thus do not meet the well-defined criteria to be classified 
as CRFs. They account for 6.1% of global HIV infections and are also critical to regional 
infections. For example, recombinants of AC, AD, CD and ACD are estimated to constitute 
about 30% of East Africa’s infections in countries like Kenya, Rwanda, Tanzania, and Uganda, 
while BF is predominant in South America, particularly Brazil and Argentina (51, 56, 80, 81). 
 
Figure 1.5: Mosaic genome structures of CRFs 
Figure 1.5: Mosaic genome structures of CRF01_AE and CRF02_AG. An alignment of representative near 
full-length strains was used and gap-stripped prior to all analysis. The HIV-1 genome map shows the position of 
each open reading frame in the gap-stripped multiple alignment. Below the genome map, each bar represents the 
mosaic pattern each CRF, adapted from (82) 
 
 
1.4 Morphology of HIV-1 
HIV-1 particles are circular in nature and comprise of 3 major components namely an envelope 
lipid bilayer, a viral matrix, and the core. The particle is surrounded by a lipoprotein membrane 
that is about 100-150 nm in diameter (83) containing 72 glycoprotein complexes integrated 
into this membrane. The lipoprotein membrane comprises of external glycoprotein trimers 
gp120 surface protein (SU) that are anchored by the transmembrane protein gp41 (TM) (84). 
The matrix p17 (MA) is anchored inside of the viral lipoprotein membrane. The viral capsid 
p24 (CA) encases two copies of HIV-1 RNA genome (83-85). The HIV-1 RNA is part of a 
protein-nucleic acid complex composed of the nucleoprotein p7 and the reverse transcriptase 
p66 (RT) (85). The viral core contains the enzymatic machinery for replication, which are the 
reverse transcriptase (RT), integrase p32 (IN) and the protease p11 (PR) (86-88). A graphical 
representation of HIV-1 particle can be seen in Figure 1.6. 
 
1.4.1 HIV-1 genome organisation 
The HIV-1 genome is organized into nine open reading frames (ORF) just short of 10 kilo 
bases in length (84, 89). The composition of the genome can be broadly classified into 
structural and accessory genes. The group-specific antigen (gag) gene encodes the matrix, 
capsid, nucleocapsid and p6 proteins; while the envelope (env) gene encodes the gp120 and 
gp41 (84, 89). The polymerase gene (pol) codes the enzymatic machinery of the virus that 
facilitates effective replication which include the enzymes. All three genes make up the 
structural genes (89, 90). The virus also has 6 accessory/regulatory genes which include virion 
infectivity factor (vif), viral protein R (vpr), viral protein U (vpu), trans-activation of 
transcription (tat), regulator of expression of virion (rev) and the negative factor (nef). The 
proteins coded for by the genes all play important roles in the replication cycle of the virus (90, 

























Figure 1.6: Graphical representation of the morphology of HIV-1 particle and Figure 1.7: 













Figure 1.6: Structure of HIV-1 virion 
Figure 1.7: HIV-1 genome map 
1.4.2 HIV-1 replication cycle 
Host cell activation, which involves the induction of cellular division is a crucial requirement 
for effective replication of HIV-1 (92). The HIV-1 replication cycle can be broadly divided 
into the following stages: a) cell binding and entry, b) viral uncoating, c) reverse transcription, 
d) viral DNA integration e) virus protein processing and assembly and f) virion budding (89, 
92, 93). Cell binding and entry is facilitated through the affinity of viral gp120 protein for CD4+ 
receptors found on a subset of T-lymphocytes and monocytes-macrophages. The binding 
between both molecules causes a conformational change allowing further interaction of gp120 
with a co-receptor on target cells such as the chemokine receptor 4 (CXCR4) or chemokine 
receptor 5 (CCR5) resulting in the fusion of the viral envelope with the target cell membrane 
(92). Following successful entry, uncoating of viral core occurs releasing viral RNA into the 
host cell cytoplasm. This is immediately followed by the conversion of single stranded viral 
RNA into a double stranded DNA by the enzymatic action of RT. Through its ribonuclease H 
active site, RT degrades the viral RNA upon completion of the reverse transcription process. 
The entire process occurs within a pre-integration complex (PIC) that comprises of MA (p17) 
protein, Vpr and IN. This PIC is then trafficked into the cell nucleus where the viral double 
stranded DNA is integrated into the host genome through the enzymatic action of IN (93). IN 
creates sticky ends at the 3’ ends of the host DNA allowing for the integration of the viral DNA 
into the host cell genome to form a pro-viral DNA. This process and the expression of the pro-
viral DNA readily occurs when the host cell is in an activated state (93). This step is followed 
by the expression of the pro-viral DNA which encodes for the viral proteins and their pre-
cursors. Expression of viral transcripts starts from the 5’ long terminal repeat (LTR) region of 
the pro-viral genome with Tat enhancing the initiation of the transcription process. Following 
successful transcription, full length and spliced viral RNAs are transported from the nucleus to 
the cytoplasm for translation and packaging of proteins. This process is facilitated by the Rev 
protein (89). Translation of viral messenger RNA (mRNA) occurs in the cytoplasm. Gag and 
Gag-Pol products are localized at the cell membrane, while translation of the env mRNA occurs 
in the endoplasmic reticulum (ER). Translation and post-translational processing of the mRNA 
result in the production of viral core proteins, MA, CA, NC, p6, PR, RT, IN and the accessory 
proteins such as Vif, Vpr, Nef, and genome RNA which leads to the gradual formation of 
immature virion and the initial step towards budding from the cell surface. The final stage of 
the process is the budding stage which also involves downregulation of surface CD4+ receptors 
by the Vpu and Nef proteins; this is to make way for the provision of SU and TM for the outer 
membrane coat during viral budding. Viral maturation occurs by proteolytic cleavage of Gag 
and Gag-Pol polyproteins by PR enzyme. At this stage, the mature virus is ready to begin 
infection of another target cell, continuing the cycle in the absence of ART (89, 92, 93). As 
mentioned in an earlier section, every step of the HIV-1 replication cycle as well as every viral 
gene product is a potential target for therapeutic interventions. Following the discovery of 
HIV/AIDS, several strategies to inhibit viral replication cycle are put into consideration during 
drug development; which include RNA based strategies such as antisense RNA, RNA decoys, 
ribozymes and protein-based strategies such as monoclonal antibodies, chimeric proteins, 
intracellular single-chain antibodies (94) and ARTs which target viral enzymes and block viral 
entry (37). Continuous investigation of HIV-1 replication cycle is critical for determining 






Figure 1.8: HIV-1 replication cycle with ART targets           
 














1.4.3 Group specific antigen (Gag) 
The group specific antigen (gag) is one of the 3 structural genes in the HIV-1 genome; it codes 
for a Gag polyprotein precursor, which when acted upon by PR leads to smaller products 
namely MA, CA, NC and p6. HIV-1 particle assembly is primarily coordinated by products of 
the gag, a machinery that recruits building blocks required for formation of a fully infectious 
viral particle, a full description of gag products, their functions and intra-cellular trafficking 
can be found in (96, 97). Its examination is of import to this thesis, and in subsequent sections 
I will elaborate on its role in viral replication. 
 
1.5 Pathogenesis of HIV-1 
Viral pathogenesis is the series of steps that occur when a viral isolate infects a susceptible host 
resulting in disease induction (98). Pathogenesis of HIV-1 infection and subsequent 
progression to AIDS are a consequence of the characteristics of the infecting viral isolate and 
the host immune response; the balance of effectiveness of both components determines the 
outcome of the infection (93). 
 
1.5.1  Primary (acute) infection 
Acute infection occurs when HIV-1 infects a susceptible host cell (98). CD4+ and follicular 
dendritic cells (FDC) near the epithelial layer represent the initial target of HIV-1 infection 
following breakthrough into the mucosal barrier (93, 99, 100). Acute HIV-1 infection is 
generally characterized by three major events namely; an initial increase in plasma viral load, 
drastic depletion of naïve resting CD4+ cells, and establishment of latent viral reservoir (101). 
The course of disease progression in an infected patient can be predicted within the first 6-12 
months of infection. This finding is based on a 1996 Multicenter AIDS Cohort Study (MACS) 
data set, that showed rapid increase in plasma viral load following primary infection up to a 
median of 106 -107 RNA copies/mL, and depletion of CD4+ count can independently predict 
whether the patient will progress quickly or slowly to AIDS (101). Within the first 10-12 days 
post infection, viral RNA can be detected in the blood using RT-PCR amplification methods. 
Following peak plasma viremia levels, HIV-1 antibodies can be detected in the patient blood 
due to humoral immune responses to the infection. This point is referred to as seroconversion 
and it is about 20-25 days on average post primary infection (93, 99). During this time the 
patient experiences flu-like symptoms such as fever, lymphadenopathy, mononucleosis, weight 
loss etc. which takes place for about 7-10 days post infection (93, 99). 
1.5.2 Chronic infection and AIDS 
Following the resolution of acute infection and the establishment of a virologic quasi-steady 
state, a prolonged period of asymptomatic chronic infection ensues (93, 101); though patients 
appear to be asymptomatic, ongoing viral replication and CD4+ depletion continues. During 
this phase, HIV-specific CTLs control viremia levels by recognizing viral antigens presented 
on the cell surface of infected cells (93). In addition, antibody dependent cellular cytotoxicity 
(ADCC) of infected cells is mediated by the natural killer (NK) cells. However, in the absence 
of therapeutic interventions, CD4+ T lymphocytes decline gradually and at a certain threshold 
(< 200 cells/μL), patients begin to suffer from certain symptoms, which constitute AIDS, such 
as prolonged fatigue, lymphadenopathy, oral and vaginal candidiasis, dermatological 










Figure 1.9: Phases of natural HIV-1 infection 
Figure 1.9: (A) Showing phases of HIV-1 natural infection (Acute and Chronic), and (B) 











1.6 Host immunity 
The human immune system comprises of a complex array of protective mechanisms including 
cells, chemicals, and processes to overcome unfortunate exposure to pathogens and their 
products that have gained entry through mucosal and epithelial surfaces of the body. An 
important feature of a functional immune system is its ability to properly discriminate between 
host cells (self) and antigens, allergens, or toxins of pathogenic origin (non-self) to avoid 
causing damage to physiological functions of the body (102). The immune system comprises 
of the innate and adaptive mechanisms which work in complement to one another to mount an 
appropriate immune response to pathogenic exposure (103-105).  
 
1.6.1 Innate immunity  
The innate immune system is organized into a network of cells (macrophages, dendritic cells, 
natural killer cells, neutrophils, mast cells, eosinophils, and basophils) and signals that act as a 
first line of defence against pathogens. The onset of HIV-1 acute infection occurs following 
breaching of the host epithelial and mucosal barriers - the host innate immune response is 
triggered by the presence of pathogen associated molecular patterns (PAMPs) which are 
recognized by pathogen recognition receptors (PRRs) found on the surface of cells of the innate 
immune system (106, 107). PRRs can be broadly divided into toll-like receptors (TLRs) and 
intracellular endosomes (108, 109). Dendritic cells are large cells encountered by HIV at 
mucosal surfaces. They transport the virus from the site of entry to the lymphoid tissue where 
follicular dendritic cells (FDCs) provide signals for activation of B-cells to attack the virus 
(109). Natural killer (NK) cells are also important for control of HIV replication (110). When 
activated they release cytokines such as interferon-γ (IFN-γ), tumour necrosis factor-α (TNF-
α) and chemokines that facilitate T-cell proliferation and have been reported to show improved 
function in the presence of KIR3DS1 HLA subtypes (110, 111).  
Unfortunately, as the infection progresses it damages components of the innate immune 
system, especially macrophages which are linked to the adaptive immune system by inhibiting 
their antigen presenting function (112). As the first line of defence, the innate immune system 
is critical for sensing the presence of HIV particles and in turn setting in motion a series of 
immunological events to activate the adaptive immune response (108, 113). 
1.6.2 Adaptive immunity 
The adaptive immune system has evolved to provide a broad and fine-tuned collection of 
component assets for the recognition of both self and non-self thereby facilitating pathogen 
specific immune responses that result in the generation of long-term immune memory and 
regulation of immune homeostasis. The evolution of the adaptive immune system is driven by 
the vast variable antigenic structures of pathogens and their tendency to evade immune 
detection. Following initial pathogen encounters, cells expressing specific immune receptors 
for pathogen recognition persist in the host for life providing immunological memory and 
capacity for rapid response in the event of re-infection. The major components of adaptive 
immunity are the T-lymphocytes which are developed in the thymus and the antibody 
producing B-cells produced in the bone marrow (114). The adaptive immune system depends 
on customized receptors selected through somatic recombination events of specific germ-line 
segments which arose by gene duplication to form intact T cell receptor (TCR) and 
immunoglobulin (B cell antigen receptor; Ig) genes early in the evolution of vertebrates for the 
purpose of generating a highly flexible and specific immune response. The germline encoding 
genes elements facilitates the development of millions of different antigen receptors conferring 
each with the potential to be uniquely specific for the vast amount of antigen it may encounter 
during an infection (103). 
 
 
1.6.2.1 T-cell immunity and HIV infection 
T-lymphocytes mature in the thymus following the migration of hematopoietic stem cells 
originating in bone marrow (104). They express a unique series of antigen-binding receptors 
on their cell membranes commonly referred to as T-cell receptors (TCR). Each T-cell expresses 
a single form of TCR and has the capacity to rapidly proliferate and differentiate based on 
reception of appropriate induction signals. Following HIV-1 infection, host experiences  
persistent immune activation, followed by decline in CD4+ cells and subsequent disease 
progression to AIDS (115) and have been shown to correlate directly with viral load and 
inversely with CD4+ count (116, 117). The major histocompatibility complex (MHC) class I 
on the cell surfaces present HIV-1 epitopes processed within the cells for recognition by TCRs 
on CD8+ T cells. CD8+ T cells then lyse HIV-1 infected cells and secrete cytokines such as 
IFN-γ, TNF-α, and chemokines such as macrophage inflammatory protein MIP-1 α and MIP 
β, that inhibit virus replication and block viral entry into CD4+ T cells. CD8+ T cells have been 
shown to be critical for control of HIV-1 replication (118-121). During acute infection, CD4+ 
T cells lose their ability to expand rapidly and therefore their contribution to viral control is 
minor, however, during chronic infection this is reversed with CD4+ T cells present and 
secreting interleukin-2 (IL-2) or cytokines, such as IFN-γ, to control viremia (117, 122). CTL 
escape is the variation in viral sequence that results in the loss of recognition by CTLs which 
is critical to the HIV pathogenesis (119). However, this in-turn impacts viral function positively 
or negatively on viral function and subsequent disease progression; and though it appears to be 
a mechanism of adaptation to its host, the range of variation of CTL epitopes is limited based 
on its impact on structure and function of the gene products (118), which further illustrates the 
effectiveness of  CTL function on viral control albeit short-lived (123).  
 
 
1.6.2.2 B-cell immunity and HIV infection 
The adaptive humoral immune system is driven by antibody production from B cells under the 
signalling influence of T cells and dendritic cells. B cells themselves, like T cells, they also 
originate from the hematopoietic stem cells in the bone marrow (114). The humoral response 
occurs later in HIV-1 infection due to the time it takes to generate appropriate antibodies. Non-
neutralizing antibodies to structural proteins such as p17 and p24 appear first but do not last. 
However, neutralizing antibodies specific to viral proteins involved in the entry of the virus 
into the cells, are subsequently produced (124). These antibodies are specific to the variable 
region of gp120 (V3), CD4+ binding sites and chemokine receptors (CXCR4 and CCR5), and 
the transmembrane protein gp41 (102).  
1.7 HIV-1 disease progression  
A complex interplay between the subtype of the infecting virus and host immunogenetics 
ultimately determine the course of disease progression in HIV-1 infected patients (125). 
Subtype-specific variation in disease progression has been widely reported among HIV-1 
infected individuals (126), with varying biological characteristics of different subtypes 
influencing rate or ease of transmission, pathogenesis, drug discovery and vaccine design (127) 
making it critical to understand the impact of these marked differences. 
1.7.1  Subtype specific differences in disease progression 
Following the discovery of HIV-1 and HIV-2, it was quickly observed that while both viruses 
descended from a common ancestor, however, a significant variance in their individual 
virulence was recognized (126). HIV-1, which is responsible for the global pandemic is more 
virulent and easily transmitted. This raised the question whether there could be differences in 
the biological characteristics of different subtypes and if this impacted disease progression. The 
best way to evaluate this question was the use of long-term natural history cohorts in the 
absence of ART (126, 128). A prospective study conducted by Kanki and colleagues 
investigated disease progression in registered female sex workers in Dakar, Senegal. The 
results of their study showed that sex workers infected with HIV-1 non-A subtypes (which was 
mostly subtype D in the cohort) progressed to AIDS or death 8 times faster than patients 
infected with subtype A (126). Subsequent prospective studies conducted in Africa by other 
groups showed similar findings; for example, a 4-year prospective study by of 1045 infected 
adults conducted in Uganda by Kaleebu et al, showed that adults infected with subtype D had  
a faster progression of disease with a relative risk of 1.29 and 95% CI and a significantly lower 
CD4 cell count compared to those infected with subtype A (127). Another 2-year study of 
pregnant women by Vasal and colleagues (2006) conducted in Tanzania showed that relative 
to subtype A, patients with subtype D experienced the most rapid progression to death or to the 
WHO stage 4 of illness (129). A 12-year study by Baeten and colleagues of 145 infected adults 
in Kenya revealed a higher mortality ratio in women infected with subtype D over those 
infected with subtype A despite having no significant difference in their viral load counts (130). 
Other studies such conducted by Kiwanuka et al (2008), and Ssemwanga et al. (2013), showed 
similar results with patients infected with subtype D having a faster progression to disease than 
those infected with subtype A in Uganda (131, 132), while a multi-site study conducted in 
Uganda and Zimbabwe by Venner et al (2016) showed similar trends in tier results, however 
this time with patients infected with subtype C having the least disease progression relative to 
A and then to subtype D (128). All these studies therefore underlie the clear observation that 








1.7.2 HIV-1 subtype-specific differences in transmission rates 
It has been particularly challenging to establish an association between HIV-1 subtypes and 
their respective risk of transmission (66, 133), however, several attempts have been made to 
demonstrate that such association exists. For example, a matched case-control study by 
Blackard and colleagues in 2001 showed that subtype A and inter-subtype LTRs were 3.2 and 
4.8 times more likely to be transmitted from mother-to-child than subtype D perinatally (134); 
another such study by Odaibo et al., 2006 highlighted a marked variance in MTCT showing a 
36.4%, 66.7% and 100% transmission in subtypes CRF02_AG, G and B in naive infected 
pregnant Nigerian women. Though the statistical power of the study was low, it did give an 
indication of the differences in the rates of MTCT based on infecting subtype (135). On the 
other hand, several risky behaviours such as intravenous drug usage, as well as hetero or homo 
-sexual relationships lead to the sustenance of HIV-1 transmission, which results in the 
segregation of HIV-1 subtypes into different groups within the population (136). For example, 
subtype B has a high transmission rate among MSMs and IDUs in Chile, Thailand, South 
Africa, Argentina, Europe, and most western countries, while non-B subtypes are more 
commonly transmitted amongst heterosexuals in those same counties (136, 137). A 
retrospective-observational study that controlled for confounders such as age, viral load, stage 
of disease, genital ulcers etc., showed that subtype A had a higher transmission potential than 
subtype AD and subtype D in Rakai, Uganda (138). Taken together, these studies highlight the 






1.7.3 HIV-1 subtype-specific functional differences  
HIV-1 subtype B is the most well characterized subtype and serves as the benchmark for 
development of therapeutic interventions, however the prospective studies conducted in Africa 
have shown that there are differences in biological characteristics of HIV-1 subtypes. With 
70% of HIV-1 infected individuals living in sub-Saharan Africa where non-B subtypes are 
most prevalent, studying disease progression in non-B subtypes is necessary in order to develop 
robust interventions that can cater for all subtypes (58). HIV-1 subtypes vary in all protein 
regions, for instance by an average of 40% and 20% within the env and gag region respectively, 
which bears a marked impact on their corresponding protein structure and function (139). For 
example, the LTR, which encodes the transcriptional promoter, has a unique configuration for 
each subtype thereby affecting rates of replication in pairwise competitive experiments (139-
141).  Similarly such functional variation had been observed in the Envelope (142) and Pol 
(143) proteins. We have also previously demonstrated the impact of subtype-specific sequence 
variation in Gag on replication capacity, where a subtype-specific hierarchy in viral replication 
capacity was observed using patient-derived sequences from East Africa (144).  In addition, 
our group observed variation in Nef’s ability to down regulate CD4+ and HLA class I allele 
expression based on subtype (145). These studies underscore the impact of HIV-1 genetic 
diversity on viral protein structure and function, it is therefore imperative to monitor their 
distribution in sub-Saharan Africa to see if these differences impact the epidemic variance 
observed in each sub-region and to account for these differences when developing therapeutic 




1.8 Viral replication capacity 
Viral fitness is simply the sum of all characteristics (mostly genetic) that contribute to the 
successful transmission of its genetic material from one generation to another under specific 
conditions such as host immune response, drug treatment (24, 25, 119), and thus accounts for 
inter subtype variation in disease progression. The inherent characteristics of HIV-1 to generate 
mutation-prone viral particles that exist as a population of genetic variants or quasi-species 
within a single infection is an evolutionary mechanism that leads to the positive selection of 
the fittest variants (22, 26, 119) that go on to establish infection in the host (24). Group M 
viruses have been shown to be more fit within the human population than their close genetic 
relatives which are the N, O, P and HIV-2 (146). However, the complex interplay between the 
viral and host-immune factors makes fitness particularly difficult to measure in vivo, hence 
viral replication capacity is used in its place within clinical and research settings as an indicator 
of the viral fitness (147). Viral replicative capacity (VRC) is an absolute measure of the ability 
of HIV-1 to replicate under standard conditions. This can be measured using several ex-vivo 
and in-vitro assays which are well described in the literature (24, 25, 148, 149). VRC impacts 
viral load, drug resistance, rate of transmission and disease progression within the host (143, 
144, 150-154) 
1.8.1 Gag function and viral replication capacity 
Gag sequences vary between HIV-1 subtypes by an average of about 14% (63, 79), revealing 
the highly conserved nature of the region and the important role it plays for effective viral 
replication. Several studies have shown how the complex interaction between viral and host-
immune factors ultimately determine disease progression in infected patients (154-157), with 
host human leukocyte antigen (HLA) composition as an individual factor correlating most 
strongly with disease progression rate (158-160). While this is logical in-vivo, it does little to 
delineate and identify viral factors that may enhance disease progression in patients who lack 
protective HLAs (154). Gag, being highly immunogenic (155) and conserved, is a prime target 
of HLA-restricted CTL responses leading to selection of viral variants with escape mutations 
that may compromise the replicative capacity of the virus and thus disease progression (154), 
especially in cases of positively linked HLA-associated mutations such in patients infected with 
HLA B*57 and B*27 which have been strongly associated with HIV-1 controllers (115). 
Previous work from our group has shown that Gag function has a significant impact on viral 
replication capacity in vitro, and strong association with markers of disease progression such 
as viral load and CD4+ count (156), suggesting that it is a suitable candidate for vaccine design 
strategies. Gag-driven variation in replication capacity within different subtypes has also been 
documented (144). 
 
1.8.1.1  Impact of Gag escape mutations on vaccine design 
The anti-viral function of CTLs is well documented. However, CTL effectiveness is limited by 
escape mutations within the dominant epitopes of HIV-1 (161-166), which are driven by the 
net balance between the immune selection pressure and fitness cost to the virus making it 
challenging to be studied in vivo (162). While there is variation in the timing of occurrence of 
escape mutations, be it at the beginning of the infection or later stages (166, 167), there is 
evidence that they are transmissible. For example, a study on perinatal transmission showed 
that escape mutations in the KK10 epitope restricted by HLA B*27 were passed on from 
infected mothers to their respective infants upon delivery (161).  However, due to the conserved 
nature of gag and the prominent role of Gag protein products in viral replicative function, 
escape mutations within particular regions of gag are limited by structural considerations 
impacting its protein products (162).  Gag escape mutations with significant costs to viral 
replication ability (as measured in vitro) were shown to be strongly associated with reduced 
viral loads when transmitted to recipients, suggesting that CTL responses focussed on 
vulnerable regions of Gag where escape is fitness costs could be of benefit to both the donor 
and recipient (168). A study by Chopera et al. 2017 showed that high frequency of escape 
mutations within different regions of gag had differential impact on disease progression with 
escape mutations within the variable regions of p17 p6p7 region leading to faster disease 
progression (167). Therefore, an in depth understanding of the replicative fitness and disease 
progression consequences of immune escape mutations bear significant implications for CTL 
based vaccine design (163, 164). It would be worthwhile to develop a prophylactic or 
therapeutic intervention that would target the specific gag regions where the generation of 
escape mutations would come at a significantly high fitness cost, weakening the capacity of 
the virus to effectively propagate itself (163, 168). HLA class one driven CTL escape mutations 
can be exploited for HIV-1 vaccine design capable of stimulating CTL responses against the 
highly conservative regions within the HIV-1 genome such as gag thereby forcing viral 
evolution towards a less-fit state (169, 170). 
 
1.9 Study rationale 
The adult prevalence rate of HIV-1 infection and its genetic diversity vary widely across sub-
Saharan Africa where an estimated 70% of global population of people living with HIV 
infection reside. This diversity bears significant impact on accurate diagnosis, rate of disease 
progression, transmission, epidemic spread, as well as the design and development of 
therapeutic interventions for controlling the epidemic. While several prospective studies have 
shown marked differences in subtype-specific rate of disease progression and transmissibility, 
there is very limited understanding of the underlying biological mechanisms which may 
account in part for the reported subtype-specific differences in disease progression or explain 
the uneven distribution and spread of subtypes in sub-Saharan Africa. The Gag protein is highly 
immunogenic and is a candidate target in HIV-1 vaccine design. Previous work from our group 
has shown that Gag-protease is an important genetic determinant of viral replication capacity 
in vitro, and that differences in Gag protease-driven replication capacity of circulating subtypes 
in South Africa and Kenya correspond with differences in disease progression rate (144, 154).  
Furthermore, studies link Gag-protease-driven replication capacity to transmission.  Therefore, 
in this study, we sought to better examine the diversity of circulating HIV-1 strains in East and 
West Africa, two regions of sub-Sharan African with distinct patterns of high versus low 
prevalence of HIV and to investigate whether there are differences in Gag-protease mediated 
replication capacity that may explain the reported differences in prevalence and subtype-
specific rates of disease progression. Moreover, we wanted to identify some of the viral genetic 
and host determinants of differences in virus replication capacity, considering that this 
information may have important implications for biomedical prevention and treatment 
strategies against HIV. 
 
1.9.1 Hypothesis 
I therefore plan to test the following hypotheses 
a) Gag-protease driven viral replicative capacity differs among HIV-1 subtypes. 
b) Viral replicative capacity is associated with indicators of disease progression such as 
viral load and CD4+ count. 
c) Host HLA Class I alleles expressed is associated with viral replication capacity in 
subtype A from East Africa. 
d) That these subtype specific differences could account for or contribute to the 
epidemiological picture of HIV-1 infection in West and East Africa. 
 
 
1.9.2 Project aims and objectives 
Specific aims: 
1. Determine if there are differences in Gag-protease-driven viral replication capacity 
according to HIV-1 subtypes.   
 
2. Associate viral replication capacities with indicators of disease progression namely 
viral load, CD4 cell counts and the rate of CD4 cell decline.   
 
3. Determine if there are subtype-specific HLA class I associations with viral replication 
capacities in the study population.   
 
4. Identify amino acid sequences associated with decreased or increased viral replication 
capacity within each subtype using all available patients.   
 
To achieve these aims the following specific objectives were fulfilled: 
 Amplification and sequencing of gag-protease of patient samples from West (n=213) 
an East (n=160) Africa. 
 Subtyping of patient derived sequences through online bioinformatic tools. 
 Recombination analysis of patient derived sequences through online bioinformatic 
tools. 
 Construction of recombinant viruses encoding gag-protease sequences derived from 
various subtypes identified from chronically infected patients West (n=178) and East 
(n=114) Africa. 
 Analysis of in vitro replication capacity for gag-protease chimeric viruses using a flow 
cytometry-based GFP-reporter T cell assay. 
 Statistical comparative analysis of in-vitro viral replication capacities of chimeric 
viruses from West and East Africa. 
 Association of gag-protease replication capacity values to HLA class I profiles of 
subtype A patients from East Africa. 
 Qualitative and quantitative analysis to determine genetic determinants of viral 






















2 MATERIALS AND METHODS 
 
2.1  Ethical Approval 
 
Ethical clearance was received from The Biomedical Research Ethics Committee (BREC) at 
the University of KwaZulu-Natal for this study (BE313/16). Stored plasma was used as study 
material and written informed consent was provided by all study participants at the time of 
recruitment. All investigations were undertaken in accordance with the principles in the 
Declaration of Helsinki.  
 
2.2  Study samples 
 
This was a retrospective cross-sectional study, where ART-naive plasma samples collected 
between the years 2000 and 2010 from chronically infected individuals in West and East Africa 
were analysed. In West Africa, study participants included ineligible blood donors, female 
commercial sex workers and members of the general population from the Cameroon (n=169) 
(171), Nigeria (n=31) (172) and Senegal (n=96) (173). In East Africa, study participants were 
from the well characterized IAVI Protocol-C cohort which included discordant couples, 
heterosexuals, and MSMs from the general population in Kenya (n=73), Rwanda (n=61) and 
Uganda (n=107). However, samples from East Africa were preselected for subtypes A, AD and 
D based on previously sequenced pol genes (174). Viral load and CD4+ T cell count data was 
available for all participants from East Africa. HLA class I data for participants infected with 
subtype A1 from East Africa was also available for analysis. Clinical and demographic 





2.3 Plasma RNA extraction 
 
Plasma samples were obtained from storage in -80°C freezer and thawed at room temperature. 
HIV-1 RNA was extracted from individual patient plasma sample using the QIAamp® Viral 
RNA Mini extraction kit (Qiagen, Hilden, Germany) according to the manufacturer’s 
prescribed protocol. Viruses from plasma samples with lower viral loads (<5,000 copies/mL) 
were concentrated by spinning 500μL of plasma sample at 14,000 rpm (rotor radius of 100mm) 
for 2 hours at 4oC. Approximately 350μL of supernatant was removed and discarded. The pellet 
was then re-suspended in the remaining volume of plasma and used for RNA extraction.  
2.3.1 Amplification and viral sequencing of Gag-protease 
Extracted viral RNA from section 2.3 was converted into cDNA and then double-stranded 
DNA by a one-step RT-PCR using the Superscript III One-Step RT-PCR, Platinum Taq High 
Fidelity kit (Invitrogen, San Diego, USA). Each reaction was made up of 14.4μL UltraPureTM 
Diethyl pyrocarbonate (DEPC) treated water (Invitrogen), 20μL of 2X reaction mix, 0.8 μL of 
each of the10μM forward Gag+1 (5’ GAG GAG ATC TCT CGA CGC AGG AC 3’; 675-697) 
and reverse 3’RVP (5’ GGA GTG TTA TAT GGA TTT TCA GGC CCA ATT 3’; 2725-2696) 
primers, 0.8 μL of Superscript III RT/Platinum Taq High Fidelity Enzyme Mix and 4μL of 
extracted RNA. The resulting reaction mixture was incubated in a thermocycler (Applied 
Biosystems, Foster City, USA) under the following cycling conditions; 55o C for 30 minutes 
and 94o C for 2 minutes followed by 35 cycles of 94o C for 15 seconds, 55o C for 30 seconds 
and 68o C for 2 minutes. The reaction ended after a final extension at 68o C for 5 minutes. A 
second round of PCR was performed to amplify the 1760bp gag-protease, HXB2 790-2550 
(175) using the Takara Ex Taq® Hot Start kit (Takara, Shiga, Japan). The 50 μL PCR reaction 
mixture included 37μL nuclease free water, 5 μL of 10Ex Taq Buffer, 4 μL 2.5mM dNTP, 0.8 
μL each of 10μM forward (GAC TCG GCT TGC TGA AGC GCG CAC GGC AAG AGG 
CGA GGG GCG GCG ACT GGT GAG TAC GCC AAA AAT TTT GAC TAG CGG AGG 
CTA GAA GGA GAG AGA TGG G; 695-794) and reverse (GGC CCA ATT TTT GAA ATT 
TTT CCT TCC TTT TCC ATT TCT GTA CAA ATT TCT ACT AAT GCT TTT ATT TTT 
TCT TCT GTC AAT GGC CAT TGT TTA ACT TTT G; 2704-2605) primers that are the 
NL4-3 sequence immediately flanking the gag-protease to facilitate homologous 
recombination, 0.25 μL of ExTaq enzyme and 2 μL of the RT-PCR product. 5 μL of the 2° 
Gag-protease amplicons of each patient was mixed with 2 μL gel loading buffer 
(SigmaAldrich, Missouri, USA) containing Gel-red nucleic acid gel stain (Biotium, California, 
USA) at a ratio of 1:50, and were resolved on 1% agarose gel (prepared using agarose tablets, 
Bioline, Atlanta, USA). The loaded gel was run at 95 volts for 1 hour to verify products of 
approximately 1760 bp (Figure 3.1) using the 1kb high DNA mass ladder (Invitrogen™, life 
Technologies Carlsbad, USA).  The gel was viewed on a Chemidoc™ imaging system using 
the Image Lab™ software version 5.0 (BioRad, CA, USA). On confirmation of the positive 
bands, the 2° amplicons were diluted in nuclease free water at a ratio of 1:15 and set aside for 
sequencing. The resulting solution was population sequenced using the ABI PRISM Big Dye 
Terminator Ready reaction mix V3 (Applied Biosystems, Waltham, USA) and run on an ABI 
3130xl Genetic Analyzer (Applied Biosystems, Waltham). The sequencing reaction comprised 
4 μL of nuclease free water, 2 μL of 5X sequencing buffer, 2.6 μL of individual primers at 
2μM concentration, 0.4 μL of Big Dye Terminator mix and 1 μL template of diluted 2° PCR. 
These 10 μL reactions were amplified in a MicroAmp® optical 96 well reaction plate (Applied 
Biosystems, Foster City, USA) at the following cycling conditions; 96o C for 1 minute, 
followed by 25 cycles of 96o C for 10 seconds, 50o C for 5 seconds and 60o C for 4 minutes. 
The sequencing products were then cleaned by adding 1 μL ethylenediaminetetraacetic acid 
(EDTA; 125 mM Sigma-Aldrich, Johannesburg, South Africa) in each well followed by 26 μL 
of the volatile mixture of sodium acetate (NaOAc; 3 M Sigma-Aldrich) and absolute cold 
ethanol (100%) at a ratio of 1:25. This was followed by centrifugation (Eppendorf centrifuge 
5810R, ThermoFisher scientific, Carlsbad, USA) of the 96 well plate at 3,000g for 20 minutes. 
Plates were then inverted on paper towel and centrifuged at 150g for 5 minutes to remove the 
liquid from the sequencing products. The pellets were immediately washed in cold 70% ethanol 
followed by centrifugation at 3,000g for 5 minutes. The liquid was removed from the plate 
again by inversion on paper towel followed by centrifugation at 150g for 1 minute. The 
products were dried at 50°C for 5 minutes in a thermocycler and stored at -20 °C (Samsung 
RZ28H6150SS, Seoul, South Korea) until further analysis on the ABI 3130xl Genetic Analyser 
(Applied Biosystems, Foster City, USA).  Sequence chromatograms generated from genetic 
analysis were assembled and edited using Sequencher v5.1 (Gene Codes Corporation, 
California, USA). Nucleotide mixtures were defined as double peaks in the sequence 
chromatogram where the secondary peak was a minimum of 25% of the height of the dominant 
peak. All plasma sequences were aligned to the HIV-1 subtype B reference strain HXB2 
(GenBank accession no. K03455) using Gene Cutter.  A summary of viral extraction to 


















Figure 2.1: Summary of amplification and sequencing of patient plasma showing 
experimental procedures from RNA extraction from patient plasma all the way to sequencing 













 Sequencing (3130xl) genetic analyser 
(Applied Biosystems) 
Figure 2.1: Amplification and sequencing summary 
2.3.2 HIV-1 subtyping  
Edited sequences were exported as a FASTA file, and were then uploaded to the REGA 
(http://www.bioafrica.net/subtypetool/html/subtypinghiv.html) HIV-1 subtyping tool v3.46 
(176) and COMET (https://comet.lih.lu/) subtyping tool (177) for independent subtype 
classification. Sequence alignment and translation was performed using the Gene-Cutter tool 
from the Los Alamos National Laboratory (LANL) database 
(https://www.hiv.lanl.gov/content/sequence/GENE_CUTTER/cutter.html)   for subsequent 
phylogenetic analyses.  
 
2.3.3 Phylogenetic analysis  
Maximum-likelihood phylogenetic trees were constructed from the multiple sequence 
alignments using PhyML (178) to determine evolutionary relationships between patient 
sequences and subtype reference strains obtained from LANL. Instances where the subtyping 
methods were not in agreement, the phylogenetic tree was used for the final subtype 
assignment.  Figtree v1.4.4 was used to infer the branching topology.  
 
2.3.4 HIV-1 subtype recombination analysis  
Prediction of inter-subtype recombination breakpoints was performed using the Jumping 
Profile Hidden Markov Model (jpHMM) online tool (179) developed by the Institute of 
Microbiology and Genetics at the Department of Bioinformatics at the University of Gottingen 
in Germany in collaboration with the Los Alamos HIV-1 sequence database 
(http://jphmm.gobics.de/jphmm.html) and the Simplot (180) program. Default settings were 
used for jpHMM, while Simplot was optimized to a window size of 350, base pair step size of 
30 and a stringent consensus value of 50%. Each identified region between breakpoints was 
extracted, trimmed, and realigned together with subtype reference sequences and phylogenetic 
trees were constructed to verify the subtype for each sequence fragment between predicted 
breakpoints. A summary of methods for HIV-1 subtyping, and inter-subtype recombination 



































Figure 2.2: Summary of HIV-1 subtyping protocol: Flow chart summarising bioinformatic 
techniques used to analyse sequence data from sequence editing to subtyping, and phylogenetic 
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Figure 2.3: Summary of HIV-1 inter-subtype recombination analysis: Flow chart showing 
two bioinformatic tools employed to predict inter-subtype recombination points, extract 
sequence fragment, and confirm subtype by phylogeny. 
  
 
2.4  Preparation of the pNL4-3∆gag-protease backbone 
 
The pNL4-3 gag-protease plasmid is available in the HIV Pathogenesis Programme 
laboratory and was prepared as originally described in (181). The plasmid contains a restriction 
enzyme BstEII site on either side of the deleted gag-protease coding region. pNL4-3∆gag-
protease plasmid stock was prepared by mixing a grown culture transformed with a glycerol-
containing cocktail of 1.6 mL LuriaBertani (LB) media (Sigma, Johannesburg, SA), 400 μL 
glycerol (Sigma) and 2 μL ampicillin in a 1:1 ratio. Large concentrations of the plasmid were 
obtained by inoculating 100 mL of LB media containing 100 μL ampicillin with 25 μL of 
thawed glycerol sock and incubated at 37oC and 230 rpm for 16-17 hours in a shaking incubator 
(Infors HT, Switzerland). The culture was then cooled to 4°C for 30-60 minutes and pelleted 
by centrifugation (Eppendorf centrifuge 5810R ThermoFisher™ scientific, Carlsbad, USA) at 
5850g for 20 minutes. The pellet was purified using plasmid maxi kit (Qiagen, Shiga, Japan) 
according to the manufacturer’s instructions and quantified using a Nanodrop 2000 
spectrophotometer (ThermoFisher™ Scientific). The purified plasmid was then frozen at             













Figure 2.3: Inter-subtype recombination analysis 
digest (ThermoFisher™ scientific). The 21 μL reaction included 15 μL nuclease free water, 2 
μL Buffer 2, 1 μL Hind III enzyme and 3 μL purified plasmid. This was incubated for 1 hour 
at 37oC. The digested products were resolved on a 2% agarose gel.  
 
2.4.1  Maintenance of the cell line 
Cell culture experiments were conducted using CEM-GXR cell lines donated by the Brockman 
group (182). They are T-cell lines that have been engineered to express the green, fluorescent 
reporter protein (GFP) to monitor HIV-1 infection levels within the cells; the cells are 
susceptible to both X4 and R5 viruses. The CEM-derived GXR GFP-reporter cells contain a 
Tat-dependent GFP expression system in which the GFP gene was inserted downstream of the 
TAR sequence in a retroviral vector. The cells were thawed from liquid nitrogen by placing 
them into a water bath at 37°C after which the cells are mixed with pre-warmed R10 RPMI 
medium with 10% foetal calf serum, 2 mM L-Glutamine, 10 nM HEPES and 50 U/ml penicillin 
–streptomycin (ThermoFisher™ scientific, Carlsbad, USA), and incubated in a humidified 
incubator at 37°C and 5% CO2 overnight. The cells were then pelleted by spinning at 1,500 rpm 
for 10 minutes and resuspended in fresh R10 removing the Dimethyl sulfoxide (DMSO) 
(Sigma-Aldrich, South Africa) a cryo-protective agent used during storage. The stock culture 
was maintained in R10 medium up to for two months. Growth medium was replaced every two 
days by discarding 50-90% of culture medium and replacing it with fresh medium. The R10 
medium contains a phenol red indicator, which changes colour from red to yellow signalling 
cell growth and consequently a need for medium replacement. The cells were used for 
experiments as required and maintained in culture for no more than 3 months before a new vial 
of GXR cells was thawed. CEM-GXRs were stored in liquid nitrogen (Antech Incorporated, 
Los Angeles, USA) within two weeks of maintenance of newly thawed GXR cells, to maintain 
consistency in all the culture experiments. Proper storage involved counting the cultured GXRs 
using TC10™ automated cell counter (BioRad, Hercules, California, USA) with the BioRad 
dual chamber counting slides. Cells were mixed with 0.4% trypan blue dye (BioRad, Hercules, 
California, USA) in a 1:1 ratio and loaded onto the counting slides. The average reading was 
used as the cell count. The ideal count was 1 million cells/ml in 40 ml flask at >90% cell 
viability.  
2.4.2  Co-transfection Experiments 
Patient-derived viral particles were generated by co-transfecting secondary (2°) Gag-protease 
amplicons from each patient and pNL4-3∆gag-protease backbone into CEM–GXR cells. 
Firstly, the reaction per gag-protease amplicon included 10 μg plasmid, 10X buffer (a tenth in 
total reaction volume), 100X BSA (one hundredth in total reaction volume), 2U BstEII enzyme 
(Promega, Madison, USA) per μg plasmid (i.e. 20 U) and nuclease free water. This reaction 
was incubated for 2 hours at 60 °C in a water bath, facilitating the linearization of the plasmid 
at the site of the gag-protease gene allowing for insertion of amplified gag-protease. The HIV-
1 gag-protease amplicons from the second round nested PCR were co-transfected with the 
pNL4-3 gag-protease by electroporation into CEM–GXR cells using the GenePulser Xcell™ 
electroporation system (BioRad, New York, USA) to generate recombinant viruses by 
homologous recombination as described by (183). A negative control CEM–GXR cells was 
electroporated with the pNL4-3∆gag-protease only. The electroporated CEM–GXR cells was 
incubated for 5 days then R10 media is added. To allow time for recombination of gag-protease 
amplicons and pNL4-3∆gag-protease plasmid, the electroporated CEM–GXR cells will then 
be incubated at 37°C and 5% CO2. On day 3 and day 5 post-transfection, 3mL and     2mL R10 
medium was added to the cell-culture flasks, respectively. Thereafter, the cultures were 
monitored every second day for infection by removing 2 mL of culture for flow cytometry 
analysis and replacing with 2 mL fresh R10 medium.   
2.4.3 Harvesting the viral stocks 
Homologous recombination of insert and vector produces infectious recombinant HIV-1; upon 
infection of new GXR cells in culture, GFP is expressed thereby allowing monitoring of 
infection by flow cytometry. On day 9 post-transfection, 2 mL of culture was removed and 
1mL of this was added to individual cluster tubes (Corning® costor, Sigma, Saint Louis, USA) 
for centrifugation at 1500 rpm for 10 minutes. The supernatant was carefully discarded, and 
the cells re-suspended in 200 μL of 2% paraformaldehyde (PFA) fixative and incubated for 10 
minutes prior to flow cytometry analysis. The fixative was prepared by dissolving 20g PFA 
(Merck, Durban, South Africa) in 500 mL phosphate buffered saline (PBS) (ThermoFisher™ 
scientific, Carlsbad, USA) at 60°C for 30 minutes on heat stir (Stuart CB162, Johannesburg, 
SA) using a magnetic stirrer. The pH of the prepared PFA was adjusted to 7.0 and stored at -
20 °C in aliquots. The thawed PFA aliquot was stored at 4°C after each use and discarded 
within 7 days of thawing.  The cluster tubes containing the fixed samples were placed in re-
usable FACS tubes (BD Biosciences, New Jersey, USA) to enable easy access to the flow cell 
chamber of the FACSCalibur (BD Biosciences). Fluorescence information was captured for 
15000 intact cells/events per sample using optimised instrument settings. The negative control 
(uninfected GXR cells) was included in each co-transfection experiment and was used to 
distinguish GFP positive cells from GFP negative cells as well as intact cells from debris. 
Gating for GFP (using the uninfected negative control sample) was set at 0.05, above which 
cells were considered GFP positive. The florescence data was analysed using FlowJo software 
(FloJo LLC, Ashland, Oregon). Upon reaching a threshold infection rate of about 25-30%, the 
culture was pelleted by centrifugation at 1700 rpm for 5 minutes at 4°C. The supernatant was 


























2.4.4 Validation of generated recombinant pNL43 RT-integrase viruses   
Validation of patient derived chimeric viruses was done as a quality control measure to ascertain 
that chimeric viruses had identical genetic composition as the original plasma viruses. RNA 
was extracted from 140μL of viral culture supernatant for 10% of randomly selected viral stocks 
using the QIAamp® Viral RNA Mini extraction kit (Qiagen, Hilden, Germany) according to 
the manufacturer’s prescribed protocol described in section 2.3. Gag-protease was amplified 







Figure 2.4: Summary of co-transfection and viral harvest protocol 
2.4.5 Titration assay  
Viral titre of stored supernatants was determined by infecting CEM–GXR cells with harvested 
virus to determine the volume of viral stock required for replication capacity experiments.  
0.4mL of virus is incubated with 0.1mL containing 1  106 CEM–GXR cells to make a final 
volume of 0.5 mL and left overnight at 37 C in a 24 well flat bottom tissue culture plate with 
a low evaporation lid (Multiwell™ 24 well Falcon BD).  Cells were then be resuspended in 
1mL R10 and incubated for a further 24 hours. The percentage of infected cells was measured 
using fluorescence-activated cell sorter (FACS Calibur, BD Sciences, New Jersey, USA) 
analysis to determine green fluorescent protein (GFP) expression at 48 h post infection. The 
titre results were used to calculate the volume of virus stock to infect GXR cells at a multiplicity 
of infection (MOI) of 0.003 for the replication capacity assay. Values were then normalized to 
those for the wild type NL4-3.  
 
Volume of virus stock = (0.3/proportion GFP-expressing cells) X 400 μL. 
2.4.6 Replication capacity assay 
The viral replication assay was performed in duplicate as previously described (154). Briefly, 
CEM-GXR cells were infected, using the same method as described in the titration assay, with 
the volume of virus stock calculated by the titration assay made up to a final volume of 0.4 mL 
using R10 medium. A negative (R10 medium) and positive (wild-type NL4-3 virus generated 
by electroporation of GXR cells with 10 μg NL4-3 wild-type plasmid) control was included in 
each assay. After a 24 hour-incubation (day one), 1 mL of R10 medium was added and the 
percentage of infected cells was monitored by flow cytometry each day for 5 days by pipetting 
out 500 μL from each well and replacing with 500 μL of fresh prewarmed R10 medium.  This 
experiment was performed in duplicate independently for each sample. The replication 
capacity of the chimeric viruses determined by Gag-protease function was calculated by the 
mean slope of exponential growth from 3-6 days post infection using the semi-log method in 
Microsoft Excel and normalised to the slope of growth of the wild-type NL4-3 control included 
in each assay to control for assay-to-assay variation. The ‘LOGEST’ function in Microsoft 
Excel calculates a log10 exponential curve that best fits the generated data and returns the slope 
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2.5 Data analysis 
 
Viral replication capacities of patient-derived chimeric viruses were compared based on      
HIV-1 subtype classification and geographical region using either the Students T test or Mann-
Whitney U test if two groups were compared, or ANOVA with Tukey post-hoc tests where 
more than two groups were compared. ANOVA was used to test for differences in replication 
capacity across each group of HLA alleles (A, B and C) for participants infected with subtype 
A1 from East Africa, while the Students T test was used to compare differences in RC values 
between participants that expressed certain class I HLA alleles and those that did not express 
such alleles.  HLA class I alleles expressed in a minimum of 5 individuals were included. These 
analyses were performed using Graphpad Prism v.8.4.3 (Graphpad Software, Sandiego, 
California, USA). A multivariable linear regression model performed using Stata 15 (StataCorp 
LLC, Texas, USA), was used to assess the relationship between subtype and VRC after 
adjusting for potential confounders. A variable was included in the final model if its inclusion 
resulted in a 10% or greater change in the coefficients of the subtype category variable. 
Multiple imputation using chained equations, was used to assess the sensitivity of results to 
missing data. Codon-by-codon Mann-Whitney U tests with q values (available at https://bblab-
hivresearchtools.ca/django/tools/codon_by_codon/) were used to identify specific amino acid 






HIV-1 sequence and VRC data generated from patient samples were correlated with markers 
of disease progression such as viral load and CD4+ count. A comparative analysis of subtype-
specific differences between gag-protease driven VRC of isolates from West and East Africa 
with the view to see if it contributes to the variances observed between both sub-regions. 
Furthermore, a multivariable regression analyses was performed to see what factors were 
driving VRC among HIV-1 subtypes between the different regions, followed by an evaluation 
of the association between HLA allele expression and viral replication capacity on East African 
subtype A1, this could unfortunately not be done for CRF02_AG in East Africa due to lack of 
HLA data. Inter-subtype recombination within the p6 region of gag was prevalent and 
investigated to see if it bore any impact on low versus high VRC. An exploratory codon-by-
codon analysis was performed to identify amino acid variants that could impact VRC in 
subtypes CRF02_AG and A1 isolates from West and East Africa, respectively.  
 
3.2 Study Participants  
 
Samples collected from HIV-infected participants from East and West Africa were analysed in 
this study. Of the 296 samples collected from West Africa, 213 (73%) were successfully 
amplified. 21% of samples from West Africa had extremely low viral load (<log 2 copies/mL), 
while 6% of samples were of low sample quality making them difficult to amplify. In East 
Africa, only 160 (66%) of the 241 samples from East Africa were successfully amplified. 
20.6% of samples had extremely low viral loads (<log 2 copies/mL) while another 13% 
appeared to be of low sample quality. A total of 178 (84%) and 114 (71%) of amplified samples 
were successfully co-transfected and assayed for replication capacity for West and East Africa, 
respectively. A disproportionately large number of subtype A1 samples failed to replicate in 
culture. Table 3.1 shows a summary of the study population demographic and clinical 
characteristics. Low sample quality is defined as samples having extremely low viral loads 
(≤Log 2copies/ml) which indicates degradation possibly due to poor storage. 
 
 
Table 3.1: Demographic and clinical characteristics of participants 
 
 
ap-values calculated using Fisher’s exact test 
bmedians with inter-quartile ranges shown in brackets 
cp-values calculated using the Mann-Whitney test 
donly 66% of participants had CD4+ T cell count data 















  West Africa East Africa p-value 
No. of participants (% male) 213 (34%) 160 (64%) <0.0001a 
Age, years (IQR)b 32 (27 – 40) 28 (24 – 34) 0.0006c 
CD4+ cells, cells/mm3 (IQR)b 478 (305 – 619)d 487 (347 – 625) 0.274c 
Viral load, log10 copies/ml (IQR)b 4.86 (4.35 – 5.37)e 4.44 (3.95 – 4.93) <0.0001c 
3.3 Sequence amplification 
 
Secondary PCR products of gag-protease amplification was confirmed using 1% Agarose gel 
electrophoresis prior to commencing the sequence procedure described in section 2.3.1. A 
representative gel of all samples successfully amplified is shown in figure 3.1 below. 
 
Gel Run Date: 13-09-2016 



























Figure 3.1: Image of secondary amplicons resolved by 1% agarose gel electrophoresis. 
3.4 HIV-1 sequence analysis 
3.4.1  HIV-1 subtyping  
HIV-1 Gag-protease sequencing and subtyping was performed on samples from patients from 
West (n=213) and East Africa (n=160) (Table 3.1).  A high level of subtype diversity was 
observed in West Africa, while this characteristic feature was less prevalent in the East African 
isolates. Subtype assignment was performed using REGA and COMET online tools 
independently so as to arrive at a consensus using bootstrap values of  >70% to demonstrate 
high confidence in subtyping results. There was a marked variance in the performance of both 
tools at subtyping sequences (Tables 3.2 and 3.3), however, this variance was resolved by 
drawing maximum likelihood phylogenetic trees to make a final decision on the sequence 
subtype assignment. 
Table 3.2: Subtyping data for West Africa 
SAMPLE 
ID 
REGA COMET Mphy 
 
BS 001   A (02_AG) A1 (check for 02_AG)* CRF02_AG  
BS 002   A (A1) A1 A1-like  
BS 003   G G G  
BS 004   G G G  
BS 005   A (02_AG) 02_AG CRF02_AG  
BS 006   A (02_AG) A1 (check for 02_AG)* CRF02_AG  
BS 009   A (02_AG) A1 (check for 02_AG)* CRF02_AG  
BS 010   A (A1) A1 A1  
BS 011  CRF02_AG ? CRF02_AG  
BS 012   G G G  
BS 013   A (A1) 02_AG CRF02_AG  
BS 014   A (02_AG) 02_AG CRF02_AG  
BS 016   A (02_AG) 02_AG CRF02_AG  
BS 019   A (02_AG) 02_AG CRF02_AG  
BS 020   A (02_AG) 02_AG CRF02_AG  
BS 021   A (02_AG) A1 (check for 02_AG)* CRF02_AG  
BS 022   A (02_AG) 02_AG CRF02_AG  
BS 023   A (02_AG) 02_AG CRF02_AG  
BS 024   A (37_cpx) 37_CPX CRF37_CPX  
BS 025   A (02_AG) 02_AG CRF02_AG  
BS 026   A (A1) 01_AE CRF01_AE  
BS 027   A (37_cpx) 02_AG CRF37_CPX  
BS 029   A (02_AG) A1 (check for 02_AG)* CRF02_AG  
BS 030   D D D  
BS 032   A (02_AG) 02_AG CRF02_AG  
BS 035  11_CPX, A1 CRF11_CPX CRF11_CPX  
BS 038   A (02_AG) 02_AG CRF02_AG  
BS 039   A (A1) 02_AG CRF02_AG  
BS 040   A (A1) CRF36_CPX CRF36_CPX  
BS 042   A (02_AG)   A (02_AG) CRF02_AG  
BS 043   A (02_AG) A1 (check for 02_AG)* CRF02_AG  
BS 044   A (02_AG) 02_AG CRF02_AG  
BS 045   A (02_AG) A1 (check for 02_AG)* CRF02_AG  
BS 046   G G G  
BS 047 F1,K ? F2  
BS 048   G G G  
BS 049   F2, K F2 F2  
BS 050   A (02_AG) 02_AG CRF02_AG  
BS 051   G G G  
BS 053   A (02_AG) A1 (check for 02_AG)* CRF02_AG  
BS 054   D D D  
BS 055   A (02_AG) 02_AG CRF02_AG  
BS 056   A (02_AG) A1 (check for 02_AG)* CRF02_AG  
BS 057 
 CRF11_CPX-
like 11_cpx CRF11_CPX 
 
BS 064   A (02_AG) A1 (check for 02_AG)* CRF02_AG  
BS 065   A (A1) ? CRF22_01A1  
BS 066   A (02_AG) A1 (check for 02_AG)* CRF02_AG  
BS 071   A (02_AG) A1 (check for 02_AG)* CRF02_AG  
BS 072  A1, F1, K ? F2  
BS 073   A (02_AG) A1 (check for 02_AG)* CRF02_AG  
BS 074   A (02_AG) 02_AG CRF02_AG  
BS 075   A (02_AG) 02_AG CRF02_AG  
BS 076   A (A1) A1 (check for 09_cpx)* CRF09_cpx  
BS 077   A (02_AG) A1 (check for 02_AG)* CRF02_AG  
BS 078   A (01_AE) ? CRF22_01A1  
BS 081   A (02_AG) 02_AG CRF02_AG  
BS 083   A (02_AG) 02_AG CRF02_AG  
BS 085   A (02_AG) 02_AG CRF02_AG  
BS 086   A (02_AG) 02_AG CRF02_AG  
BS 088   A (01_AE) 01_AE CRF01_AE  
BS 090   A (A1) 01_AE CRF01_AE  
BS 092 CRF11_cpx ? CRF11_CPX  
BS 094   A (02_AG) 02_AG CRF02_AG  
BS 096   A (02_AG) 02_AG CRF02_AG  
BS 097   A (A1) A1 A1  
BS 099   A (02_AG) 02_AG CRF02_AG  
BS 101   A (A1) A1 CRF45_cpx  
BS 102   A (02_AG) 02_AG CRF02_AG  
BS 105   A (02_AG) 02_AG CRF02_AG  
BS 107   A (A1) 01_AE CRF22_01A1  
BS 114   A (A1) 01_AE CRF22_01A1  
BS 115   A (A1) ? CRF22_01A1  
BS 117   A (02_AG) A1 (check for 02_AG)* CRF02_AG  
BS 118  CRF11_CPX 11_cpx CRF11_CPX  
BS 119   A (02_AG) 02_AG CRF02_AG  
BS 120 CRF02_AG 02_AG CRF02_AG  
BS 123   A (02_AG) 02_AG CRF02_AG  
BS 125   A (02_AG) 02_AG CRF02_AG  
BS 126  A2 A2 A2  
BS 129 CRF02_AG 02_AG CRF02_AG  
BS 130 CRF02_AG 02_AG CRF02_AG  
BS 133   H H H  
BS 135   H H H  
BS 136 D D D  
BS 137   A (02_AG) A1 (check for 02_AG)* CRF02_AG  
BS 139   D D D  
BS 140   A (02_AG) 02_AG CRF02_AG  
BS 141   G G G  
BS 142   A (02_AG) 02_AG CRF02_AG  
BS 143   A (02_AG) 02_AG CRF02_AG  
BS 144  A(01_AE) A1 CRF01_AE  
BS 145   A (01_AE) 01_AE CRF22_01A1  
BS 147   A (02_AG) 02_AG CRF02_AG  
BS 159   A (A1) A1 CRF45_cpx  
BS 160  CRF11_CPX 11_cpx CRF11_CPX  
BS 163   A (02_AG) A1 (check for 02_AG)* A1, G  
BS 166  G, A1 ? A1, G  
BS 168 CRF02_AG 02_AG CRF02_AG  
BS 170 G, A1 ? A1, G  
BS 175   A (01_AE) 01_AE CRF22_01A1  
BS 178   A (02_AG) 02_AG CRF02_AG  
BS 179   D D D  
BS 180   A (02_AG) A1 (check for 02_AG)* CRF02_AG  
NG 001 G, A1* ? CRF43_02G  
NG_002 CRF02_AG-like ? CRF02_AG  
NG 003  G G G  
NG_006 CRF02_AG 02_AG CRF02_AG  
NG 007  G ? G  
NG 012  G G G  
NG 032 CRF02_AG A1(check for 02_AG)* CRF02_AG  
NG 033 CRF02_AG CRF02_AG CRF02_AG  
NG 035 CRF02_AG 02_AG CRF02_AG  
NG 036  G G G  
NG 038  G G G  
NG 039 CRF02_AG 02_AG CRF02_AG  
NG 046 CRF02_AG CRF02_AG CRF02_AG  
NG 050  G G G  
NG 053 CRF02_AG CRF02_AG CRF02_AG  
NG 069 02_AG, G ? CRF02_AG  
SN 001  CRF02_AG 02_AG CRF02_AG  
SN 002  CRF02_AG 02_AG CRF02_AG  
SN 003  C C C   
SN 004   A (02_AG) A1/02_AG* CRF02_AG  
SN 005   A (02_AG) 02_AG CRF02_AG  
SN 006  CRF02_AG 02_AG CRF02_AG  
SN 007   A (A1) A1 A3  
SN 008  CRF02_AG A1/02_AG* CRF02_AG  
SN 009 09_cpx, A1, G* ? CRF02_AG  
SN 010   A (A1) A1/02_AG* CRF02_AG  
SN 011  CRF02_AG 02_AG CRF02_AG  
SN 012  CRF02_AG A1/02_AG* CRF02_AG  
SN 013   A (02_AG) A1/02_AG* CRF02_AG  
SN 014  CRF02_AG 02_AG CRF02_AG  
SN 015   A (02_AG) 02_AG CRF02_AG  
SN 016  CRF02_AG 02_AG CRF02_AG  
SN 017  CRF02_AG 02_AG CRF02_AG  
SN 018   A (02_AG) 02_AG CRF02_AG  
SN 019  CRF02_AG 02_AG CRF02_AG  
SN 020   A (02_AG) 02_AG CRF02_AG  
SN 021   A (02_AG) 02_AG CRF02_AG  
SN 022   A (02_AG) A1/02_AG* CRF02_AG  
SN 023  CRF02_AG ? CRF02_AG  
SN 024  CRF02_AG ? CRF02_AG  
SN 025   A (02_AG) 02_AG CRF02_AG  
SN 026   A (02_AG) A1/02_AG* CRF02_AG  
SN 027  CRF02_AG A1/02_AG* CRF02_AG  
SN 028   A (02_AG) 02_AG CRF02_AG  
SN 029   A (02_AG) 02_AG CRF02_AG  
SN 030  CRF02_AG 02_AG CRF02_AG  
SN 031   A (A1) A1 A3  
SN 032  CRF02_AG 02_AG CRF02_AG  
SN 033  CRF02_AG 02_AG CRF02_AG  
SN 034  CRF02_AG 02_AG CRF02_AG  
SN 035  CRF02_AG 02_AG CRF02_AG  
SN 036   A (02_AG) 02_AG CRF02_AG  
SN 037  CRF02_AG 02_AG CRF02_AG  
SN 038   A (02_AG) 02_AG CRF02_AG  
SN 039  CRF02_AG A1/02_AG* CRF02_AG  
SN 040  CRF02_AG 02_AG CRF02_AG  
SN 041   G* 06_cpx CRF06_cpx  
SN 042  CRF02_AG 02_AG CRF02_AG  
SN 043   A (A1) 01_AE CRF22_01A1  
SN 044  G, A1* ? CRF06_cpx  
SN 045  CRF02_AG 02_AG CRF02_AG  
SN 046   A (A1) A1 A3  
SN 047  CRF02_AG 02_AG CRF02_AG  
SN 048   A (A1) A1 A3  
SN 049  CRF02_AG 02_AG CRF02_AG  
SN 050  CRF02_AG 02_AG CRF02_AG  
SN 051  CRF02_AG 02_AG CRF02_AG  
SN 052  CRF02_AG 02_AG CRF02_AG  
SN 053   A (A1) A1 A3  
SN 054  CRF02_AG A1 (02_AG) CRF02_AG  
SN 055   A (02_AG) A1 (02_AG) CRF02_AG  
SN 056   G G G  
SN 057  CRF02_AG A1 (02_AG) CRF02_AG  
SN 058   A (02_AG) 02_AG CRF02_AG  
SN 059  CRF02_AG A1 (02_AG) CRF02_AG  
SN 060   D D D  
SN 061   A (02_AG) A1 (02_AG) CRF02_AG  
SN 062   A (02_AG) 02_AG CRF02_AG  
SN 063  CRF02_AG ? CRF02_AG  
SN 064   A (02_AG) 02_AG CRF02_AG  
SN 065   A (A1) ? A3  
SN 066  CRF02_AG ? CRF02_AG  
SN 067  CRF02_AG ? CRF02_AG  
SN 068   G G G  
SN 069 02_AG, A1 ? CRF02_AG  
SN 070  CRF02_AG ? CRF02_AG  
SN 071  CRF02_AG ? CRF02_AG  
SN 072   D D D  
SN 073  CRF02_AG ? CRF02_AG  
SN 074 A1 ? CRF02_AG  
SN 075   D D D  
SN 076   A (A1) A1 A3  
SN 077  CRF02_AG 02_AG CRF02_AG  
SN 078  CRF02_AG A1 (02_AG) CRF02_AG  
SN 079   A (A1) A1 A3  
SN 080  CRF02_AG A1 (02_AG) CRF02_AG  
SN 081  CRF02_AG A1 (02_AG) CRF02_AG  
SN 082   A (02_AG) A1 (02_AG) CRF02_AG  
SN 084  CRF02_AG ? CRF02_AG  
SN 085 CRF02_AG ? CRF02_AG  
SN 086   A (02_AG) A1 (02_AG) CRF02_AG  
SN 087  CRF02_AG A1 (02_AG) CRF02_AG  
SN 088   A (02_AG) 02_AG A3  
SN 089   A (A1) A1 (02_AG) CRF02_AG  
SN 090   A (02_AG) A1 (02_AG) CRF02_AG  
SN 091   B B B  
SN 092 A1, G A1, G A1, G  
SN 093  A1, G ? CRF02_AG  
SN 094   A (02_AG) 02_AG CRF02_AG  
SN 096 A1 ? A3  
 












Table 3.3: Subtyping data for East Africa 
SAMPLE ID REGA COMET Mphy 
 
PC 002  A (A1) A1 A1  
PC 003 A1, C A1C* A1C   
PC 004  A (A1) A1 A1  
PC 005  A (A1) A1 A1  
PC 006  A (A1) A1 A1  
PC 008  A (A1) A1 A1  
PC 009  A (A1) A1 A1  
PC 010  A (A1) A1 A1  
PC 011 A1 A1 A1  
PC 012 C, A1 ? A1C  
PC 013 A1, C A1C* A1C  
PC 014  A (A1) A1 A1  
PC 015 D, A1 A1D* A1D  
PC 016  A (A1) A1 A1  
PC 017  A (A1) ? A1  
PC 018  A (A1) A1 A1  
PC 020  A (A1) A1 A1  
PC 022  D D D  
PC 023  D D D  
PC 025  D D D  
PC 026 A1, D ? A1D  
PC 027  A (A1) A1 A1  
PC 028  A (A1) A1 A1  
PC 029  A (A1) A1 A1  
PC 030  A (A1) A1 A1  
PC 031  A (A1) A1 A1  
PC 032  A (A1) A1 A1  
PC 033  A (A1) A1 A1  
PC 034  A (A1) A1 A1  
PC 036 C, A1 A1C* A1C  
PC 039 A1, D ? A1D  
PC 040  A (A1) A1 A1  
PC 041  A (A1) A1 A1  
PC 042  A (A1) A1 A1  
PC 043  A (A1) A1 A1  
PC 046 C, A1 A1C* A1C  
PC 047  A (A1) A1 A1  
PC 049  D D D  
PC 050  A (A1) A1 A1  
PC 051 A1, D ? A1D  
PC 053 A1, D ? A1D  
PC 054  D D D  
PC 055  A (A1) A1 A1  
PC 056 A1D A1D A1D  
PC 057  A (A1) A1 A1  
PC 058  D D D  
PC 060  D D D  
PC 061  A (A1),  A1 A1D  
PC 062  A (A1)-like A1D* A1D  
PC 063 A1 A1 A1  
PC 066  D D D  
PC 067  A (A1) A1C* A1  
PC 068  D D D  
PC 070 A1 A1 A1  
PC 071 D, A1 A1D* D  
PC 076  A (A1) A1 A1  
PC 077  A (A1) A1 A1  
PC 078 A1 A1 A1  
PC 079 A1, H ? A1D  
PC 080 A1 A1 A1  
PC 081  A (A1) A1 A1  
PC 083  A (A1) A1 A1  
PC 087  A (A1) A1 A1  
PC 088  A (A1) A1 A1  
PC 089  A (A1) A1 A1  
PC 092  A (A1) A1 A1  
PC 093  A (A1) A1 A1  
PC 095  D D D  
PC 096 A1, D A1D* A1D  
PC 097  A (A1) A1 A1  
PC 098  A (A1) A1 A1  
PC 099  D A1 D  
PC 100 A1 A1 A1  
PC 101  A (A1) A1 A1  
PC 104  A (A1) A1 A1  
PC 105  A (A1) A1 A1  
PC 106  A (A1) A1 A1  
PC 107  A (A1) A1 A1  
PC 109  A (A1) A1 A1  
PC 112  A (A1) A1 A1  
PC 113  A (A1) A1 A1  
PC 114  D A1D* A1D  
PC 116  A (A1) A1 A1  
PC 117  A (A1) A1 A1  
PC 118  A (A1) A1 A1  
PC 121 A1 A1 A1  
PC 122  A (A1) A1 A1  
PC 123 D D D  
PC 125  D D D  
PC 128  A (A1) A1 A1  
PC 129  A (A1) A1 A1  
PC 132  A (A1) A1 A1  
PC 137  A (A1) A1 A1  
PC 141  A (A1) A1 A1  
PC 142 A1, D ? A1D  
PC 143  A (A1) A1 A1  
PC 144  A (A1) A1 A1  
PC 148 A1 A1 A1  
PC 149 D D D  
PC 150 A1, D A1D* A1D  
PC 151  A (A1) A1 A1  
PC 154  A (A1) A1 A1  
PC 155 A1 A1 A1  
PC 158  A (A1) A1 A1   
PC 159  A (A1) A1 A1  
PC 161  A (A1) A1 A1  
PC 162  A (A1) A1 A1  
PC 163  D D1 D  
PC 164  A (A1) A1 A1  
PC 165 D, A1 A1D* D  
PC 166  D D D  
PC 167 D, A1 A1D* A1D  
PC 168  D D D  
PC 170  D D D  
PC 171  D D D  
PC 172  D D D  
PC 173  A (A1) A1 A1  
PC 174  A (A1) A1 A1  
PC 175 A1, D A1D* A1D  
PC 176  A (A1) A1 A1  
PC 177  A (A1) A1 A1  
PC 178  D D D  
PC 179  A (A1) A1 A1  
PC 181  D D D  
PC 182  D D D  
PC 183  D D D  
PC 185  D D D  
PC 186  D D D  
PC 187  D D D  
PC 188  A (A1) A1 A1  
PC 190  D D D  
PC 191  D D D  
PC 192  D D D  
PC 193  D D D  
PC 194  A (A1) A1 A1  
PC 195  A (A1) A1 A1  
PC 196  D D D  
PC 197  A (A1) A1 A1  
PC 198  A (A1) A1 A1  
PC 199  A (A1) A1 A1  
PC 200  A (A1) A1 A1  
PC 201  A (A1) A1 A1  
PC 202  A (A1) A1 A1  
PC 203  A (A1) A1 A1  
PC 204  A (A1) A1 A1  
PC 205  A (A1) A1 A1  
PC 206  A (A1) A1 A1  
PC 213  D D D  
PC 217  A (A1) A1 A1  
PC 222  A (A1) A1 A1  
PC 223 D, A1 ? A1D  
PC 224  A (A1) A1 A1  
PC 225  A (A1) A1 A1  
PC 227 A1D A1D A1D  
PC 229  A (A1) A1 A1  
PC 230  A (A1) A1 A1  
PC 232  A (A1) A1 A1  
PC 233  A (A1) A1 A1  
PC 235  A (A1) A1 A1  
PC 239 A1, D ? A1  














3.4.2 Sequence Phylogenetic Analysis  
Phylogenetic analysis was conducted by drawing maximum likelihood trees using the online 
PhyML tool on the LANL database. The trees showed clustering of patient derived query 
sequences with their corresponding reference sequences downloaded from the LANL. 
CRF02_AG which was the most predominant subtype formed two sub-clusters within its major 
cluster which were largely country specific for Cameroonian sequences and a separate cluster 
for Senegalese/Nigerian seqeuences. CRF06_cpx and CRF11_cpx formed their independent 
clusters, while CRF09_cpx, CRF45_cpx, A1, A3, and A2 all formed different lineages from 
within the A1 cluster which showed how closely related these subtypes were. Furthermore, 
recombination analyses of these CRFs showed that they were pure subtype A1 within the gag 
region, hence their positioning on the phylogram. Due to the closeness of CRF01_AE and 
CRF22_01A1, the online tools found it challenging to distinguish between both and in most 
cases identified them as pure A1. On the other hand, phylogenetic analysis was able to resolve 
both into separate clades despite their close genetic relatedness. Other CRFs such as 
CRF36_cpx, CRF37_cpx and CRF43_02G formed their own separate lineages, though 
CRF43_02G was very close to the pure subtype G cluster. Pure subtypes such as B, C, D, F2, 
G, and H were also identified in West Africa making it highly diverse as shown in Figure 3.2A, 
while Figure 3.2B showed the branching topology within the West African tree to highlight 
how the different subtypes related to one another. In East Africa, the phylogenetic analysis 
showed that there is less diversity within the region.The major clusters within the maximum 
likelihood tree were subtype A1, A1D and D, there was to a much less extent subtype A1C 
(Figure 3.3). Having identified subtype A1 and D as common denominators within each region 
(though they were more predominant in East Africa), another phylogenetic analysis was 
performed comparing these subtypes which showed the presence of region-specific 
evolutionary adaptation within subtypes (Figure 3.4). 
Figure 3.2: Phylogenetic analysis of gag-protease sequences for West Africa 







Figure 3.2: Phylogenetic analysis of gag-protease sequences for West Africa (A) 
Maximum-likelihood phylogenetic tree showing all gag-protease sequences in a polar tree 
layout; and (B) phylogram layout to highlight relationships between each cluster using the 
PhyML tool on the LANL HIV database. Subtypes and inter-subtype recombinants were 
confirmed using reference sequences downloaded from the LANL HIV database. Subtype 
classification was colour coded as shown in the key. Branches representing subtype reference 
sequences are labelled in black. 
A1 A2 A3 B C 
CRF01_AE CRF02_AG CRF06_cpx CRF09_cpx CRF11_cpx 
CRF22_01A1 CRF36_cpx CRF37_cpx CRF43_02G CRF45_cpx 

































Figure 3.3: Phylogenetic analysis of gag-protease sequences for East Africa. Maximum 
likelihood trees were constructed using the PhyML tool on the LANL HIV database. Subtypes and 
inter-subtype recombinants were confirmed using reference sequences downloaded from the LANL 
HIV database. Subtype classification was colour coded as shown in the key. Branches representing 
subtype reference sequences are labelled in black. 
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Figure 3.3:Phylogenetic analysis of gag-protease sequences for East Africa 
 




Figure 3.4: Maximum likelihood tree showing common subtypes A1 and D in West and East 
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3.4.3 HIV-1 subtype geographic distribution 
CRF02_AG was the most prevalent circulating subtype in West Africa at 65%, followed by 
subtype G and A3 at 7% and 5% respectively, while the remaining pure subtypes and CRFs 
were present at <5% prevalence Figure 3.5A. It was also the most predominant subtype across 
the 3 different countries. It was interesting to note an apparent decline in subtype A1 across the 
region. Cameroon and Senegal seemed to have the most genetic diversity of the three countries 
within the region, though more sampling from Nigeria would give more information about the 
diversity of its epidemic. Senegal was the only country with subtype A3 (Figure 3.5 D). 
Cameroon had the most complex expidemic within the region (Figure 3.5B).  
 
To extend previous analysis of Gag-protease subtype in East Africa (144) by our group, we 
increased the sample size for the most prevalent subtypes in the region. Preselected subtypes 
A, D and AD recombinants based on previous Pol subtyping data (174) were used. The data 
showed that subtype A1 was most prevalent in the population sampled followed by subtype D, 
A1D and A1C (Figures 3.6 A-D). Subtype A1 remained the most predominant in Kenya and 
Rwanda (Figures 3.6 B and C). In Uganda there was almost an equal split between subtype A1 
(40%) and D (44%), which was follwed by URF A1D at 16% (Figure 3.6D). 80% of URF A1D 












Figure 3.5: Subtype distribution in West Africa 
 
Figure 3.5: Subtype geographical distribution. Genetic subtype distribution in West Africa 






























































Figure 3.6: Subtype distribution in East Africa 
 
Figure 3.6: Subtype geographical distribution in East Africa. Genetic subtype distribution 






























































3.4.4 Gag-protease inter-subtype recombination analysis 
There are a myriad of bioinformatics methods and tools that are employed to infer HIV-1 
subtypes and inter-subtype recombination patterns; however, following trials with different 
tools, the REGA, jpHMM and Simplot (184) tools were chosen for my analysis. These three 
methods were used to complement and validate one another due to inherent limitations in each 
tool, thereby increasing confidence in the accuracy of the results. Wherever there was conflict 
between tools, 2 out of 3 that were in concordance with one another would be chosen (Figure 
3.7), and the results still confirmed through phylogenetic analysis of the fragments of the 
sequences (Figure 3.8). Inter-subtype recombination analysis within the gag-protease region 
indicates that all HIV-1 CRFs and other recombinant forms in West and East Africa are 
recombinants of A1 (Figure 3.9). In West Africa, the analysis shows that the most prevalent 
inter-subtype recombinants were those of subtypes A1 and G, and less common inter-subtype 
recombinants were combinations of A1 and J, or A1, G and J, with CRF02_AG being the most 
common followed by CRF11_cpx. In the gag region, the remaining West African CRFs were 
close genetic relatives of subtype A1 (CRF01_AE, CRF09_cpx, and CRF22_01A1, 
CRF36_cpx, CRF37_cpx and CRF45_cpx) or A1, G (CRF06_cpx and CRF43_02G) 
recombinants. Majority of the inter-subtype recombinants have a breakpoint within the p6 
region in gag-protease. In East Africa, inter-subtype recombination patterns between subtype 
A1 and C or A1 and D were identified. All 5 A1C recombinants were identified from Rwanda 
and had subtype A component towards the -3’end of the sequences, while 80% (n=12) of all 
A1D identified originated from Uganda where A1 and D co-circulate in approximately equal 
proportions, with subtype D (80%) being the predominant component at the -3’end of the 
sequences. This recombinant pattern is consistent with previous work done in our group (144) 
indicating an evolutionary preference in A1D inter-subtype recombinant Gag sequences for 










Figure 3.5: Subtype geographical distribution. Genetic subtype distribution in East Africa 






Figure 3.7: A representative output showing different bioinformatic tools used to infer 
inter-subtype recombination analysis in HIV-1 sequences.  REGA (A) and Simplot (B) both 
used bootstrapping method to compare query sequences to reference sequences while the 
jpHMM (C) uses posterior probability to infer recombination points within the sequences. 
Tools were not always in agreement, however a concordance of 2 out of 3 was acceptable to 
infer recombination coordinates. Black arrows point at predicted recombination points along 








Figure 3.8: Phylogenetic confirmation of sequence fragments 
 
Figure 3.8: Phylogenetic confirmation of sequence fragments. Predicted sequence fragments by 
REGA, Simplot and jpHMM tools were further confirmed using phylogenetic analysis by extracting 
sequence fragment and drawing maximum likelihood trees. Sequence fragments clustered with their 
respective reference sequences. Number indicated in the figure is the actual nucleotide position within 
the sequence where the inter-subtype recombination took place. Numbering on figure represents actual 





Figure 3.9: Inter-subtype recombination analysis 
Figure 3.9: Graphic summary of inter-subtype recombination patterns within HIV-1 gag-protease 
from West and East Africa. Consensus sequence patterns of recombinants circulating within different 
countries in West Africa. Individual sequences are represented in East Africa. The number of sequences 
identified are indicated in brackets. Missing sequence data is shown in yellow. Gene lengths and 
breakpoints were drawn according the HXB2 numbering.   
. 
nt 
3.5 Gag-protease replication capacity analysis 
3.5.1  Distribution and variability of replication capacity assay 
The VRC of patient-derived gag-protease chimeric viral stock was reported as the slope of 
viral spread from day 3-6 post-infection in comparison to that of the control NL4-3 strain. The 
assays were performed in independent duplicate experiments. The frequency distribution was 
driven by the prevalent subtype in each region which were subytpes CRF02_AG and A1 in 
West and East Africa respectively. In West Africa VRC distribution was skewed to the right 
(Figure 3.10A) showing higher mean VRC among subtypes within the region, while a normal 
distribution was observed on the East African histogram (Figure 3.10B) showing a more 
balanced distribution in the VRC within the region. Duplicate independent measurements 
performed to validate experiments and results were highly concordant. They were reported as 
the average of the two measurements. Spearman and Pearson correlation analysis were 
performed for West (Figure 3.10C) and East (Figure 3.10D) Africa respectively based on their 
frequency distribution patterns. 
  
 
Figure 3.10: VRC distribution analysis for West and East Africa. 
 
 
Figure 3.10: VRC distribution and variation in West and East African Isolates (A and B); 
distribution and reproducibility of gag-protease driven replication capacity assay in West and 
East Africa (C and D) by performing duplicate measurements for all samples. RC-1 is 1st 
replicate for all RC samples, while RC-2 is the second replicate. This experiment was done to 
demonstrate how reproducible the assay is.
3.5.2 Correlation of VRC with markers of disease progression 
Previous work from our group have shown strong association of VRC with markers of disease 
progression in subtype C from South Africa and various subtypes from East Africa (143, 144, 
154); here, VRC of all isolates regardless of their region were correlated with viral load and 
CD4+ counts separately. The results showed a weak positive correlation between viral load 
measured in log10 copies/mL and VRC (Spearman correlation r = 0.12; p = 0.071), while it 
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negatively correlated with CD4+ count measured in cells/μL (Spearman correlation  r = -0.06;  
p = 0.322).  
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r = -0.06; p = 0.322
Figure 3.101: VRC and markers of disease progression 
 
 
Figure 3.11: Gag-protease driven viral replication capacity and markers of disease progression 














3.5.3 Gag-protease driven replication capacity in West and East African subtypes 
Previous work from our group showed that there was subtype hierachy in gag-driven VRC 
(144) and the literature had also shown that individuals infected with certain subtypes 
progressed faster over patients infected with other subtypes (126, 128, 131, 185). We 
hypothesised that these subtype-specific differences in VRC could contribute to the mosaic 
nature of the epidemic in sub-Saharan Africa. To evaluate these observations, a comparative 
analyses was performed using the student t tests and ANOVA to identify possible subtype 
specific differences in gag-protease-driven VRC. Overall, viruses from West Africa had 
significantly higher VRC compared to those from East Africa (Figure 3.12A). A subsequent 
comparison of the most prevalent circulating subtype in each region showed that CRF02_AG, 
which was most predominant in West Africa had a higher viral replication capacity than 
subtype A1 (Figure 3.12B) which was the most predominant subtype from the samples 
collected in East Africa, indicating that the prevalent subtypes were driving the overall 
difference in VRC observed between both regions. The same subtypes – A1 and D - compared 
between regions showed no difference in viral replication capacity according to region     
(Figure 3.12C and D). In West Africa pure subtype A1 had the lowest gag-protease driven 
VRC when compared to subtypes D, G, CRF02_AG, and CRF11_cpx; and though A1 was 
used as the reference subtype for this analysis, other genetically close A1 relatives like 
A3/CRF22_01A1 also had significantly lower gag-protease driven VRCs compared to the 
other subtypes (Figure 3.13A). In East Africa pure subtype A1 also had the lowest gag-protease 
driven replication capacity when compared to other subtypes, and a hierarchy  of 
A<A1C<A1D<D was observed, which is consistent with previous reports by our group (144) 
(Figure 3.13B). Comparison between the most prevalent CRF and URF in West and East 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.5.4 Multvariable regression analysis (West and East Africa) 
Multvariable linear regression was used to assess the relationship between subtype and VRC. 
However, potential confounders such as participant’s sex, age and viral load counts which were 
significantly higher in West African participants than in East African participants (Table 1) had 
to be controlled for. Historically, men have been shown to have higher viral loads than women 
(186), and this higher viral load and sex bears an impact on the region’s VRC (150, 187) 
making it was necessary to decouple all them. There were 196 participants with sequence-VRC 
pairs from West Africa, 91 (46.4%), 14 (7.1%) and 91 (46.4%) from Cameroon, Nigeria, and 
Senegal, respectively. Viral Load measurements were only available for participants from 
Cameroon, and CD4+ count measurements were only available for 48 participants from 
Cameroon and 84 participants from Senegal. Information in age was only available for 84 
participants from Cameroon. In West Africa, the most frequently observed subtype was 
CRF02_AG which was observed in 139 (~71%) of participants with sequence-VRC pairs. In 
the univariate analysis, subtypes A1, A1G recombinants, A3 and CRF22_01A1 were all 
associated with significantly lower VRC when compared to CRF02_AG. Under 25% of 
participants had complete information on all the following parameters: CD4+ count, viral load, 
and VRC, rendering the construction of a multivariable or imputation model challenging. In 
view of country being a significant predictor of VRC, and country-specific missing data 
patterns, we constructed separate multivariable models for Cameroon and Senegal (but not 
Nigeria due to the small sample size) to gain insight into the effect of subtype on VRC while 
adjusting for confounders (Table 3.4). The country-specific multivariate models collectively 
supported the significant findings in the univariate analysis: A1, A1G recombinants, A3 and 
CRF22_01A1 had 0.49 (p < 0.0001), 0.35 (p = 0.01), 0.2 (p = 0.03) and 0.4 (p < 0.0001) 
significantly lower mean VRC compared to CRF02_AG.  
In East Africa, the most frequently observed subtype, A1, was found in 103 (64%) of 
participants. 5 (3.1%), 17 (10.6%) and 35 (21.9%) of participants were subtypes A1C, A1D 
and D, respectively; however, only 114 participants had seqeunce-VRC pairs which were 
included in the regression models. In the univariate analysis, A1D and D subtypes were 
associated with significantly higher VRC values, after adjusting country, CD4 count, viral load, 
age and gender. Using multiple imputation with multivariate regression the dataset was 
imputed 50 times and estimates were combined on the imputed dataset, yielding revised 
regression estimates. After multiple imputation A1D had a 0.24 significantly higher mean VRC 
compared to A1 (p < 0.001), while D had a 0.29 significantly higher mean VRC compared to 
















Table 3.4:Multivatiable model associating subtype and VRC for West Africa. 
 
Univariate model Multivariate model 
  West Africa Cameroon Senegal 
Observations 166 77 66 
Prob > f <0.0001 <0.0001 0.022 
r2 0.290 0.653 0.193        
aSubtypes Co-efficient p-value Co-efficient p-value Co-
efficient 
p-value 
A1 -0.388 <0.0001 -0.489 <0.0001 - - 
A1Gb -0.190 0.013 -0.012 0.854 -0.352 0.010 
A3 -0.250 <0.0001 - - -0.199 0.032 
CRF11_cpx 0.033 0.691 -0.006 0.907 - - 
CRF22_01A1 -0.038 <0.0001 -0.398 <0.0001 - - 
D 0.093 0.187 0.024 0.681 0.137 0.308 
G -0.017 0.775 -0.098 0.223 -0.067 0.768        
Meta data             
Age - - -0.001 0.629 - - 
Log VL - - 0.033 0.054 - - 
CD4+ count - - - - 0.000 0.137 





Table 3.5: Multivariable model associating subtype and VRC for East Africa. 
 
 



















































  Univariate model Multivariate model 
Observations 114 111 
Prob > f <0.0001 <0.0001 
r2 0.30 0.34      
aSubtypes Co-efficient p-value Co-efficient p-value 
A1C 0.07 0.5 0.113 0.298 
A1D 0.25 <0.0001 0.239 <0.0001 
D 0.31 <0.0001 0.292 <0.0001      
bCountry           
Rwanda - - -0.075 0.272 
Uganda - - -0.032 0.622  
  
  
meta data       
Age - - -0.003 0.175 
Log VL - - 0.012 0.727 
CD4+ count - - <0.0001 0.858 
Sex - - -0.034 0.481 
3.5.5 HLA alleles associated with Gag-Protease driven replication capacity 
Genome wide association studies (GWAS) have demonstrated that the Human Leucocyte 
Antigen (HLA) class I alleles are the most significant genetic determinant of clinical outcome 
in HIV-1 infection (188). To investigate the impact of HLA allele expressed on the Gag-
protease driven VRC on subtype A1 patient-derived isolates from East Africa, VRC data were 
grouped according to HLA alleles expressed by the hosts for each loci (Figure 3.11). VRC did 
not differ significantly overall between the different HLA-A (Figure 3.11A), HLA-B (Figure 
3.11B) and HLA-C (Figure 3.11C) alleles. However, an analysis of individual HLA alleles 
showed that HLA-A*23:01 and HLA-C*07:01 were strongly associated with lower VRC 
(Student’s T test; p = 0.0014 and p = 0.002) respectively, while HLA-B*07:02  was strongly 
associated with higher VRC (Student’s T test; p < 0.05). This analysis could not be done on 
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Figure 3.134: VRC association with HLA class I expression 
Figure 3.14: Associations between HLA class I allele expression and Gag-protease driven 
replication capacity. Gag-protease driven viral replication capacities (VRC) of chronically infected 
participants from East Africa with subtype A1 infection were grouped according to HLA class I alleles 
expressed. The box plots display VRC results arranged from lowest median VRC at the bottom and the 
highest median VRC at the top. Boundaries of the boxes indicate the interquartile ranges, while the 
whiskers display the maximum and minimum RC values. The continuous vertical line on each graph 
indicates the median VRC (0.6560) for all subtype A1 viruses. HLA-I alleles with a minimum of n = 5 
are shown. Asterisks indicate HLA alleles that are significantly (p < 0.05) associated with either higher 











3.5.6 Gag p6 subtype predicts VRC 
Depending on the subtype, the Gag p6 is a 50-52 amino-acid protein unique to lentiviruses such 
as HIV-1. It contains the PTAPP and LYPLASL motifs which interact with the host cell 
TSG101 and Alix factors respectively to facilitate efficient virion maturation and budding from 
host cells (189, 190). Recombination patterns in West and East Africa showed a preference for 
subtypes D, G or J rather than subtype A in the p6 region of Gag, highlighting an important 
evolutionary trait that may impact VRC. In support of this, a comparative analysis of East 
African recombinants with A1 and D components within the p6 region showed a significant 
difference between the groups, where sequences with a subtype D p6 had a higher VRC              
(p = 0.0021 ; Figure 3.15A). Previous reports (191) and work from our own group (144) support 
that variation in the LYPLASL motif in gag affects VRC. Therefore, to investigate subtype-
specific amino acid sequence in the PTAP and LYPLASL motifs of the p6 region of gag, 
consensus sequences of individual subtypes irrespective of region was generated A1 (n=104), 
A1D (n=16), A3 (n=10), CRF02_AG (n=139), CRF11_cpx (n=5), CRF22_01A1 (n=8), D 
(n=43) and G (n=15) and aligned with HXB2 subtype B sequence as a reference. While amino 
acid sequence in the PTAP domain remained conserved irrespective of subtype, there were 
marked variations in the LYPLASL domain.  Highlighted in Figure 3.15B are the sequence 
variations in Alix motif of p6 by subtype and how these correspond to subtypes of low versus 
high replication capacity. Further work to interrogate the effect of these subtype specific 




















Figure 3.14: Amino Acid variation in Gag p6 region 
Figure 3.15: Analysis of the amino acid sequence of the p6 region of Gag. Analysis of the 
amino acid sequence of the p6 region of Gag. (A) Comparative analysis of VRC of A1D 
recombinants with A1 and D components respectively within the p6 region of gag. (B) 
Consensus amino acid sequence of subtypes A1, A3, CRF02_AG, CRF11_cpx,                  
CRF22_01A1, D, and G show mutations within the Alix motif showing which sequences 
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3.5.7 Sequence codon-by-codon analysis 
An exploratory codon-by-codon analysis to identify amino acid polymorphic variants 
associated with differences in VRC was performed for the predominant subtypes in West 
(CRF02_AG) and East (A1) Africa using methods previously described (143). The analysis 
identified several amino acid polymorphisms that associated with altered VRC at p < 0.05, 
however, upon correction for multiple codon comparisons none of the associations met the 
significant threshold of q < 0.2 (Tables 3.6 and 3.7). In CRF02_AG sequences, A83V, a 
previously inferred escape variant (165) in known CTL epitopes in the p17 region of gag was 
the only non-consensus amino acid variant associated with a lower VRC (Table 3.6). This result 
was consistent with previous reports linking A83V to reduced viral fitness in subtypes B and 
CRF01_AE (165, 192). In subtype A1 sequences, the only non-consensus polymorphism 
associated with decreased VRC was P497L, while non-consensus amino acid variants K69Q, 
S125N, L147I, A158V and R380K, were associated with significantly higher VRC (Table 3.7).  
However, the consensus amino acids at positions 12 and 28 were associated with increased 
VRC, which suggests that mutations at these codons, within known CTL epitopes, confer a 
fitness cost. Consistent with this, polymorphisms at codon 28 have been reported to alter VRC 
in other subtypes (155, 193). Further work is required to validate these findings since the 








Table 3.6: Codon-by-codon analysis for subtype CRF02_AG 
aConsensus 
AA/Codon 




with aa  
Median 
Replication 






without aa  
p-value  q-value  A-list epitope  
 
L34 L 0.91 0.95 83 27 0.022 0.525 
KW9 (A*2402), HL9,  
LF11 (A*30) 
 
L34 I 0.95 0.91 27 83 0.022 0.525  
A83 A 0.93 0.73 109 6 0.015 0.525 RY11 (B*0801),             
SL9 (A*0201, A*0202, 
A*0205), SY10 (A*0201),  
LY9  (A*2902, B*4403) 
 
A83 V 0.73 0.93 6 109 0.015 0.525  
S125 S 0.91 0.95 69 40 0.029 0.525 NY9 (B*3501)  
A146 N 1.00 0.91 13 101 0.006 0.514 
GI8 (B*1302), HL9 
(B*1510), QW11 (A*2501), 
IW9 (B*5701, B*63) 
 
E260 D 0.97 0.91 19 96 0.011 0.525 
NY10, PY9 (B*3501),       
EI8 (B*0801) 
 
E260 E 0.91 0.97 94 21 0.017 0.525  
V267 V 0.91 0.94 58 56 0.032 0.525 
EI10(B*0801), RK10 
(B*2703), KK10 ( B*2705) 
 
V267 I 
0.94 0.91 56 58 0.032 0.525  
S332 A 
1.04 0.92 5 110 0.005 0.514 DL9 (B*0801)  
R335 R 0.91 0.95 73 40 0.025 0.525 
DL9 (B*0801) 
 
R335 K 0.95 0.91 40 73 0.025 0.525  
aThis column represents the consensus amino acid at specified at that locus; bThis column represents the amino acid 












Table 3.7: Codon-by-codon analysis for subtype A1 
Consensus 
AA/Codon 
AA    Signal Median 
Replication 
with aa  
Median 
Replication 
without aa  
No. of 
patients 
with aa  
No. of 
patients 
without aa  
p-value  q-value  A-list epitope  
 
K12 K 0.68 0.23 52 8 0.045 0.862 GI9 (B*4002)  
K28 K 0.69 0.47 45 13 0.008 0.862 RK9 and RY10 ( A*0301)  
A67 A 0.63 0.82 57 5 0.023 0.862 -  
K69 Q 0.77 0.63 8 52 0.048 0.862 -  
S125 N 0.76 0.63 8 52 0.042 0.862 NY9 (B*3501)  
L147 I 0.79 0.63 5 55 0.039 0.862 GI8 (B*1302), HL9             ( 
B*1510) QW11 (A*2501), 
IW9 (B*5701, B*63) 
 
V158 V 0.63 0.75 54 9 0.038 0.862 
VF (B*1503) 
 
V158 A 0.75 0.63 9 54 0.038 0.862  
I223 I 0.63 0.73 49 14 0.028 0.862 HA9 (B*3501, B7) 
 
R380 K 0.75 0.63 9 53 0.036 0.862 -  
P497 L 0.54 0.68 16 42 0.021 0.862 -  
aThis column represents the consensus amino acid at specified at that locus; bThis column represents the 




























A hallmark of the HIV-1 epidemic in sub-Saharan Africa is its heterogeneity in terms of adult 
prevalence rates and viral subtype diversity. Marked variance in prevalence rates across sub-
regions has been widely reported such that southern African countries tend to have the highest 
adult prevalence rates followed by East African countries, while West and Central African 
countries having the lowest prevalence rates (50, 51, 194).  It is also noteworthy that HIV-1 
subtypes are unevenly distributed across the continent, with subtype C being predominant in 
southern Africa, subtypes A, D, C and their recombinants are common in East Africa and 
almost all known subtypes have been identified to be present in West-Central Africa (51, 195).  
The possible contribution of viral genetic and functional characteristics to the uneven 
distribution of subtypes is unresolved. Differences in transmission efficiency and rate of 
disease progression have been confirmed in epidemiological and clinical studies, suggesting 
that viral factors may partially explain the heterogeneity in prevalence and uneven spread of 
HIV-1 subtypes within the continent (126, 127, 134, 135, 138, 144, 196).  In this study, samples 
from HIV-1 infected drug naïve individuals from 3 West African countries (Cameroon, 
Nigeria, and Senegal) and 3 East African countries (Kenya, Rwanda, and Uganda) were 
analyzed in order to perform a comparative analysis of the epidemic in both regions using 
patient-derived gag-protease sequences which have been reported previously to be a strong 
determinant of VRC. I then analyzed the data according to geographic regions and viral 
subtypes with a view to gain further insights into how viral characteristics are associated with 




4.1 HIV-1 diversity and geographical distribution 
 
The HIV-1 epidemic in West Africa displayed a higher level of subtype diversity than that of 
East Africa, which was consistent with previous surveillance data from both regions (61, 63, 
171, 174, 197). West Africa has been theorized to be where the cross-species transmission 
events occurred which gave rise to the group M HIV-1 lineage that is responsible for the global 
pandemic (3, 10, 15, 16, 20). This suggests that all subtypes expanded out of the region into 
the different parts of the world through migration, trade and other possible early human 
interactions (10), however, it is interesting to note that while subtypes A1 and D were common 
to both West and East Africa, though in significantly higher proportions in East Africa, the 
expansion of other subtypes such as B, F, G, H, J and K have rarely been reported in East 
Africa. This suggests that subtype evolution and expansion into different regions could be 
driven by a combination of viral factors and host genetic factors such as HLA which select for 
the fittest variants and allow for their subsequent expansion within a specific region (119, 163). 
It is therefore critical to consider HLA class I expression and other host genetic factors within 
each region’s population to identify any differences that may account for the subtype 
differences observed within both regions. Furthermore, research efforts into the development 
of a universal vaccine that can address HIV-1 subtype diversity should be intensified in West 








4.2 In-vitro VRC was higher in West African Isolates 
 
This data showed that VRC varied widely among subtypes both inter and intra regionally. 
Overall, isolates from West African displayed a higher gag-protease driven VRC than isolates 
from East Africa. CRF02_AG and A1 were the most prevalent subtypes in West and East 
Africa respectively, with both subtypes being the main drivers of VRC within their respective 
regions. CRF02_AG had a significantly higher VRC than A1 (Figure 3.12B). The VRC in both 
West and East African isolates differed significantly by HIV-1 subtype with a clear hierarchy 
where A1/A3 had generally lower VRC when compared to pure subtypes D and G or A1 
recombinants except for A/C recombinants with a median = 0.71 and CRF22_01A1 (median = 
0.46), the latter being a very close genetic relative of A1. My data is thus consistent with 
previous studies of Gag-protease functional differences among HIV-1 subtypes and 
recombinants that may also be extended to other HIV-1 proteins (140, 142, 145, 198-201).  
Enhanced gag-protease-driven VRC has been associated with faster rate of CD4+ T cell decline 
and disease progression (156), and my data is consistent with reported subtype-specific 
differences in disease progression (126-128).  Descriptive statistical analysis of the combined 
gag-protease driven VRC data for West and East African participants gave a median of 0.86. 
This allowed for the categorization of the VRC values into low or high, -values less than the 
median were considered low while those higher were categorized as high. HIV-1 surveillance 
studies have shown that adult prevalence rate is much lower in West Africa than in East Africa. 
However, the current study shows that overall, West African isolates have a higher gag-
protease driven VRC than the East African isolates even after controlling for potential 
confounders such as sex, age of participants, plasma viral load and CD4+ count. This is 
consistent with the hypothesis that higher replication capacity is associated with lower 
transmission potential.  
There are a couple of plausible mechanisms described in literature by which these observations 
could be rationalized; these include the theory of evolution of virulence in pathogens, and 
functional differences driven by gag-protease VRC amongst different HIV-1 subtypes. The 
evolution of virulence theory proposed that intermediary virulence is likely to maximize the 
fitness of a pathogen as it facilitates a much-required balance between its ongoing replication 
and its onward transmission within susceptible members of the population which results in a 
trade-off between virulence and transmission (202). In RNA viruses such as HIV-1, several 
factors such as transmission bottlenecks, accumulation of deleterious mutations and within host 
adaptation affect evolution of virulence by driving down its severity (202-205). In time, these 
impact virulence and in-turn reduce transmission potential of the virus. The data from the 
current study points towards functional differences in gag-protease driven VRC among 
regional HIV-1 subtypes as another reason for the observed inverse relationship between adult 
prevalence rate and prevailing subtype transmission potential.  Previous work from our group 
showed a strong correlation between gag-protease-mediated VRC and the VRC of whole 
isolates (144). As highlighted in the introductory chapter, prospective studies have clearly 
shown that time of infection to AIDS/death varies amongst HIV-1 subtypes (126-132); and 
others have shown that in vitro VRC to be a predictor of in vivo VRC or viral fitness, which in 
turn impacts disease progression in infected patients (24, 119, 148, 149, 206). Putting all these 
together, it is proposed that patients infected with subtypes with higher VRC progress to 
disease/death faster than those infected with subtypes lower VRC making it easier for the latter 
to transmit the virus to other members of the population according to the evolution of virulence 
theory. This may explain the observation that in East Africa, subtype A1 which was shown to 
have a lower VRC is more transmissible compared to subtype D and yet the latter has been 
associated with a faster rate of disease progression (130-132, 202, 207). 
On the other hand, in West Africa a recombinant form of A1 has become predominant 
suggesting that recombination may be a mechanism that both compensates for replication 
capacity defects while allowing adaptations that facilitate transmission, another factor that may 
influence the expansion of CRF02_AG in West Africa could be prevalent HLA-I expression 
that selects for the subtype. A 2005 comparative study of VRC of group M, O and HIV-2  
isolates which showed that VRCs of group O and HIV-2 isolates were significantly lower than 
their group M counterparts and by implication, this limited viral function impaired their 
transmission potential causing them to be restricted to west-central Africa (146); hence if our 
hypothesis is accurate these subtypes should be the most prevalent globally. However, these 
contrasting positions could possibly be explained by significant difference in respective viral-
host adaptations between group M, N, O, P and HIV-2 isolates. In summary, group M, N and 
HIV-2 isolates represent multiple cross-species transmissions into the human population (3, 
10, 15, 16, 20, 21), and a consequence of the evolutionary pathway of group M viruses has 
made them the most adaptable to the human population (146); thereby making subtypes within 
this clade able to thrive above and beyond group N, O, P and even HIV-2 isolates. Nevertheless, 
further studies of other genetic determinants of transmission enhancement are required.   
 
It is also noted from the data, that studies of inter-subtype recombinants may be informative. 
Specifically, that non-A subtype was preferred for the p6 region of Gag. Recombination 
patterns suggested that the 3’ region of the Gag protein is a recombination hotspot particularly 
for A1 recombinants. The p6 contains two well studied segments, the PTAP and LYPLASL 
domains which interact with the host cell TSG101 and Alix factors respectively to facilitate 
efficient virion maturation and budding from host cells (189, 190). Whereas the PTAP motif 
showed no amino acid variation across subtypes, the LYPLASL motif showed variation across 
subtypes which corresponded to either low or high VRC. Furthermore, a comparative analysis 
of East African recombinants with A1 and D components within the p6 region showed a lower 
VRC for those with subtype A1 (p < 0.05). We and others have shown previously that variation 
in the Alix budding motif in Gag affects viral replication capacity (144, 191). Further work to 
interrogate the effect of these subtype-specific amino acid variations within the LYPLASL 
motifs on VRC is warranted.  
 
4.3 Impact of HLA expression on subtype A1 
 
Isolates from the East African cohort had complete HLA data, and since subtype A1 was the 
most predominant within the region we decide to evaluate the impact of HLA allele expression 
on VRC of patients infected with subtype A1 from the region, this was done as a follow-up to 
similar work done by our group on subtype C from Southern Africa. We identified HLA class 
I alleles associated with differences in VRC in this study, VRC did not differ significantly 
across HLA-A, HLA-B and HLA-C alleles. However, HLA-A*23:01 and HLA-C*07:01 were 
associated with lower replication capacity, suggesting an underappreciated role in immune 
selection pressure on HIV-1 subtype A1 by certain HLA-A and HLA-C alleles.  This finding 
appears consistent with previous findings of subtype-specific differences in HLA-driven viral 
evolution that may have consequences for natural and vaccine-mediated immunity (208).  
Overall, the data highlights the need for further studies to identify mechanisms of immune 
control or regions of viral vulnerability by HLA alleles common in regions of the world with 






4.4 Recombination as a mechanism for increased fitness in subtype A1 
 
Recombination analyses of the West African isolates identified several CRFs, consistent with 
the multiple pure subtypes that have been identified within the region (16). In West Africa, 
most recombinants comprised of A1 and G genetic fragments and breakpoint analysis 
suggested that recombination patterns were not random, with a strong preference for subtype 
G or J over A1 at the 3’-end of most recombinant or mosaic sequences, with a recombination 
hotspot around the Gag p6 region. A similar trend was noted for the East African isolates where 
there was also a preference for subtype D over A within the same region in recombinant 
sequences. Overall, the data suggested that subtype A1 in both West and East Africa has a high 
propensity for inter-subtype recombination with non-A subtypes at its 3’ end particularly from 
around the Gag p6 region; [96% (146/152) of West and 80% (12/15) of East African 
recombinants had a break point within the p6 region of gag]. It is therefore hypothesized that 
this could be a mechanism to facilitate the adaptation of HIV-1 subtype A1 into a fitter virus.  
Indeed, it has been reported that throughout sub-Saharan Africa, pure forms of subtype A1 are 
in decline, with a concomitant increase in its recombinants (51).  The notion that recombination 
may be a non-random mechanism to enhance viral fitness is backed up by our replication 
capacity data. Except for A1C, all other A1 recombinants had higher VRC than the median 
VRC of the total population studied, with A1C having slightly lower VRC than the median. 
Furthermore, direct comparison of the most prevalent A1 recombinant in West (CRF02_AG) 
and East (A1D) Africa showed no significant difference in their VRC as opposed to when both 
are compared with pure subtype A1 which showed a significant difference and therefore 
attribute this difference to the recombination event within the p6 region of gag. We found that 
inter-subtype recombination within gag-protease was non-existent within less common West 
African CRFs such as CRF01_AE, CRF22_01A1 CRF09_cpx CRF45_cpx due to their very 
close genetic relatedness to subtype A1 within the gag-protease region. 
4.5 HIV-1 subtyping 
 
Accurate regional HIV-1 genetic surveillance is critical in directing public health response to 
accurate diagnosis and confirmation of prevalent subtype(s), its impact on viral 
transmissibility, virulence, disease progression, drug resistance and very importantly, vaccine 
development efforts to complement the efficacy of ARTs in reducing viral transmission (57, 
63, 197). In the past, the heteroduplex mobility assay (HMA) was commonly used to identify 
HIV-1 genetic subtypes (63, 209, 210); however, in more recent times, it has been replaced 
with more sophisticated multiple online bioinformatic tools developed for the same purpose 
since they are more user friendly. However, each tool comes with its own strengths and 
limitations, hence the need to explore different approaches to increase confidence that the right 
subtype is being identified. In this study the REGA and COMET tools were used independently 
to confirm subtype of each isolate. Both tools accept FASTA format which can be uploaded as 
a file or pasted into the space created on each tool for sequences. REGA seemed to give the 
more comprehensive report of HIV-1 subtyping by mapping the nucleotide positions of the 
query sequence to HXB2 reference sequence, it also provides a pie chart summary of subtypes 
identified and highlights possible drug resistance mutations in its report output; due to the 
multiple analyses it conducts, it takes moderately longer time to process each sequence, as 
opposed to COMET which has a much faster output, but with very limited information other 
than HIV-1 subtype identified. Both algorithms are limited by the training/reference sequence 
data set used to identify subtypes, so an expansion of the training/reference sets used is critical 
for accurate subtype identification, especially with the expansion of new pure subtypes, CRFs 
and URFs. In many cases both tools could not distinguish between pure subtype A1, 
CRF01_AE and CRF22_01A1 due to how closely related these lineages are. Other CRFs such 
as CRF09_cpx and CRF45_cpx were assigned subtype A1 because there was no recombination 
event within the gag region of these subtypes, and so by implication, the initial subtyping 
results overestimated the incidence of A1 in West and even East Africa. Phylogenetic analysis 
which is the generally accepted gold standard for HIV-1 subtyping (211) was used to resolve 
discrepancies between both tools and final subtype assignment. Phylogenetic analysis has more 
control with the number of reference sequences that can be used to train the algorithm in 
subtype assignment process, it is therefore highly recommended that phylogenetic analysis be 
used to confirm any subtyping exercise. The methods used to arrive at subtype interpretation 
are consistent with current methods currently being employed (73, 212) giving confidence in 
the subtyping results obtained which bears significant impact on the subsequent downstream 
analysis of the sequences generated, and equally relevant within clinical settings where it is 
imperative to consider HIV-1 subtype when designing and implementing new preventative and 
therapeutic strategies such as vaccines (174, 213). 
 
4.6 Study limitations 
 
Limitations of the current study include missing clinical data such as CD4+ T cell counts and 
HLA-I genotypes, particularly for the West African samples, thus limiting the robustness of 
statistical analysis. East African samples were preselected for subtypes A, D and their 
recombinants based on prior pol genotyping and therefore not allowing for comprehensive 
inter-subtype comparison of the strains that constitute the East Africa epidemic.  It should also 
be noted that all replication assays were performed in the subtype B pNL4-3∆gag-protease 
backbone, however, we have previously demonstrated that viral replication data generated from 
this assay is generally reflective of whole virus isolates in HIV-1 subtype C. The study 
compared VRC of HIV-1 subtype C isolated from patients and the corresponding NL4-3 
recombinant viruses encoding Gag-protease derived from the same patients. The results 
showed a significant positive correlation between both groups (144, 154).   
 
A higher sample size would also have benefited the robustness of the codon-by-codon analysis 
to identify amino acids associated with altered VRC. Another limitation of the study was the 
singular use of GXR cells to perform the replication capacity analysis. The study would have 
benefitted from the use of multiple cell lines to see if differences in cell lines could impact the 
viral replication capacity. It is likely that the cell line or cell type used for the replication assay 
could influence result outcomes.  Nevertheless, the advantage of using the GXR cell line for 
the assay is that it is optimised for high throughput, and it has an indicator system that allows 
analysis of replication capacity using a flow cytometry-based assay.  Moreover, it shows good 
correlation of replication capacity of viruses when compared with assays performed in 
peripheral blood mononuclear cells (144).  
 
4.7  Future Work and recommendations 
 
My project focused on gag-protease as a virological factor that drives VRC as well as HIV-1 
viral diversity in sub-Saharan Africa, with a minor emphasis on immunological factors that 
may drive escape mutations. Immunological factors in combination with viral genetic factors 
highlighted within this thesis ultimately determine the variance in adult prevalence and HIV-1 
subtype diversity observed in sub-Saharan Africa.  
 
Expansion of this study will strongly benefit from investigating immunological factors that 
also contribute to the epidemiological picture of both regions studied. An exploratory 
transcriptome wide association study to profile upregulated and downregulated host genes that 
determine immune responses to infection by different HIV-1 subtypes could be investigated. 
Data from this work could be critical in answering the questions as to why certain subtypes 
irrespective of their VRC are more prevalent in certain locations over others, why there is a 
strong compartmentalization of HIV-1 subtypes between different regions. It is plausible that 
infection with viruses with high VRC could cause aberrant gene expression profiles that leads 
to elevated immune activation leading to faster disease progression independent of viral load. 
The identification of host molecules that are differentially expressed in infected cells may lead 
to novel interventions to counteract the effects of viruses with high VRC. The study will 
therefore be performing an exploratory transcriptome-wide analyses to identify host factors 
and genetic pathways that may distinguish between uninfected cells, and cells infected with 
viruses with high VRC and those with low VRC. This study could provide important insights 
on intrinsic differences between subtypes to explain epidemiological spread and disease 
progression rates and may help to advance rational vaccine design approaches for these 
subtypes. The approach could be by way of ligation mediated RNA sequencing (LM-RNA-
Seq) which is a modified, but less costly RNA-Seq protocol as described by Hou et al., 2015 
(214). cDNA libraries will be constructed, mRNA is isolated from purified 100 ng total RNA 
using oligo-dT beads (NEB). Based on data generated from VRC assays, selection of the 20 
high VRC viruses and 20 low VRC viruses will be made and put through the transcriptome 
gene expression experiments in cells infected with these as well as uninfected cells. Isolated 
mRNA is fragmented in reverse transcription buffer with heat and then reverse-transcribed with 
SmartScribe reverse transcriptase (Clontech) using a random hexamer oligo. Following reverse 
transcription, RNA is removed by RNaseA and RNAaseH treatment. A partial illumine 59 
adaptors is then ligated to the single stranded cDNA using T4 RNA ligase 1 (NEB) and 
incubated overnight at 22°C. Following purification, ligated cDNA is amplified by 18 cycles 
of PCR using oligos that contain full illumine adaptors. The cDNA library is thereafter 





Due to the possible limitation associated with using only pNL4-3∆gag-protease backbone to 
generate chimeric viruses for my study, it will be useful to consider generating full length HIV-
1 genomes for a smaller number of patient derived sequences. Full-length genome primers 
could be designed and optimized for subtypes with high VRC from West Africa such as 
CRF02_AG and CRF11_cpx, and those with low VRC such as CRF01_AE and CRF22_01A1, 
while full length sequences can be generated for subtypes A1 with low VRC and subtypes A1D 
and D from East Africa. VRC assay will be conducted using the protocol outlined in Chapter 
3, and the data generated can be compared to the VRC data generated from my study to see if 
there are similar trends, or if other genetic loci are bearing significant impact on overall VRC.  
This approach is particularly important to address the disproportionate poor growth of subtype 
A1 isolates in culture which could be because of poor compatibility with the NL4-3 backbone.  
 
Further investigation is also warranted to critically review the hypothesis that viruses with 
lower VRC are more successfully transmitted within the population studied than those with a 
higher VRC as an evolutionary mechanism to ensure sustained transmission within the 
population.  It is possible that viral variants with lower replication capacity are preferentially 
transmitted because they induce a less prominent innate immune response (such as type I 
interferons) upon exposure to cells in the genital tract, thus facilitating the establishment of 
infection, as opposed to a more robust innate immune response that may lead to viral clearance.  
Our group has also previously proposed that viruses with lower replication capacity may be 
associated with a longer infected cell half-life, which could potentially then favour cell to cell 
transmission of these viruses compared to viruses with higher replicative capacity that may 
quickly kill carrier cells and thus lessen the probability of transmission (144).  Studies to better 
understand the effect and kinetics of transmission of viruses with high versus low replication 
capacity particularly in cells within the genital tract that are the portal of entry in most 
heterosexual transmission of HIV in sub-Saharan Africa are warranted. Supernatants from 
infected cell cultures of different subtypes can be collected and measured for IFNα to via flow-
cytometry to subtype-specific induction of immune responses which could address the 
hypothesis raised in my study. 
 
Variance in viral characteristics such as host adaptation and viral function amongst the different 
HIV-1 groups can be evaluated by methods such as growth competition assay which have the 
advantage of directly comparing the growth and virulence characteristics of isolates exposed 
to the same cells in culture to see which viruses expand over one another or have other 
cytopathic effects (24, 148). Viral adaptation and transmission efficiency could further be 
established by engineering cell-lines with specific receptor on cells to see which isolates will 
still be able to replicate despite the limited receptors available on the cell lines. For example, 
T-cells lines with R5 and X4 receptors, cells with either R5 of X4 receptors and cells with 
neither of these receptors as a negative control, as a positive control cells with both receptors 
but receptor blocking agents introduced into the culture. Furthermore, enzyme kinetic studies 
of orthologs within different isolates could also be performed to evaluate their respective 
functional capacity (215); these are some proposed methods of evaluating viral fitness and host 
adaptability that could further validate results from the present study and test the hypothesis 
generated as well. Another means of measuring transmission efficiency would be to collect 
culture supernatants of infected cells and quantify IFNα expression via flow-cytometry, the 
immune response data collected can then be matched to the HIV-1 strain that establishes 
infection which will give an overview of how well it is able to establish infection in the 
presence or absence of adequate immune responses. This can be further matched with genetic 
regulatory pathway data generated from the exploratory transcriptome wide association study. 
It is possible that viral variants with lower replication capacity are preferentially transmitted 
because they induce a less prominent innate immune response (such as type I interferons) upon 
exposure to cells in the genital tract, thus facilitating the establishment of infection, as opposed 
to a more robust innate immune response that may lead to viral clearance. Our group has also 
previously proposed that viruses with lower replication capacity may be associated with a 
longer infected cell half-life, which could potentially then favours cell to cell transmission of 
these viruses compared to viruses with higher replicative capacity that may quickly kill carrier 
cells and thus lessen the probability of transmission (144).  Studies to better understand the 
effect and kinetics of transmission of viruses with high versus low replication capacity 
particularly in cells within the genital tract that are the portal of entry in most heterosexual 
transmission of HIV in sub-Saharan Africa are warranted.   
 
Finally, though the adult prevalence rate in West Africa is lower relative to other parts of sub-
Saharan Africa, the population affected is still significantly high and ART coverage programs 
are relatively low due to poor execution unlike in eastern and southern Africa. A renewed focus 
on HIV-1 research work in terms of VRC and HLA class-I expression within the region is 
urgently needed, being ground zero for the cross-species transmissions and global spread of 
the global HIV-1 epidemic, concentrated efforts within the region could yield to faster 

















Overall, in this study we show that HIV-1 viruses from West Africa displayed higher VRC 
than those from East Africa, consistent with the hypothesis that higher prevalence is associated 
with lower replication capacity of circulating strains. Subtype-specific differences in 
replication capacity in agreement with previous studies were noted, and consistent with 
reported differences in the rate of clinical disease progression. Our study identified inter-
subtype recombination pattern as a driver of VRC differences and identified specific amino 
acid that may alter VRC. Validation of these amino acids in additional studies is required. 
Finally, our study identified HLA-A class I class to have a differential impact on HIV-1 
replication capacity for HIV-1 subtype A1, the predominant subtype in East Africa which 
suggest the need for further studies to identify regions of viral vulnerability for HIV-1 vaccine 
design strategies. 
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